

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent, with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/

09/744167

JCS6 REC'D PCT/PTO

19 JAN 2001

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty:

The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

For International Preliminary Examining Authority use only

Identification of IPEA	Date of receipt of DEMAND
------------------------	---------------------------

Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION		Applicant's or agent's file reference 3206-172/PAR
International application No. PCT/CA99/00656	International filing date (day/month/year) 20 July 1999 (20.07.99)	(Earliest) Priority date (day/month/year) 20 July 1998 (20.07.98)
Title of invention SARA PROTEINS		

Box No. II APPLICANT(S)	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) HSC Research and Development Limited Partnership 555 University Avenue Suite 5270 Toronto, Ontario M5G 1X8 Canada	Telephone No.: Facsimile No.: Teleprinter No.:

State (that is, country) of nationality: CA	State (that is, country) of residence: CA
--	--

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) WRANA, Jeffrey L. c/o HSC Research and Development Limited Partnership 555 University Avenue Suite 5270 Toronto, Ontario M5G 1X8 Canada	
--	--

State (that is, country) of nationality: CA	State (that is, country) of residence: CA
--	--

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)	
--	--

State (that is, country) of nationality:	State (that is, country) of residence:
--	--

☐ Further applicants are indicated on a continuation sheet.

DOCUMENT PROCESSING
BRANCH
01 JAN 23 AM 8:02

Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The following person is ☒ agent ☐ common representative
 and ☒ has been appointed earlier and represents the applicant(s) also for international preliminary examination.
☐ is hereby appointed and any earlier appointment of (an) agent(s) /common representative is hereby revoked.
☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.

Name and address: (Family name followed by given name; for a legal entity, full official designation.
 The address must include postal code and name of country.)

Patricia A. Rae (Dr.)
 SIM & McBURNEY
 6th Floor
 330 University Avenue
 Toronto, Ontario
 M5G 1R7
 Canada

Telephone No.:

416-595-1155

Facsimile No.:

416-595-1163

Teleprinter No.:

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION**Statement concerning amendments:***

1. The applicant wishes the international preliminary examination to start on the basis of:

☒ the international application as originally filed

the description



as originally filed



as amended under Article 34

the claims



as originally filed



as amended under Article 19 (together with any accompanying statement)



as amended under Article 34

the drawings



as originally filed



as amended under Article 34

2. ☐ The applicant wishes any amendment to the claims under Article 19 to be considered as reversed.

3. ☐ The applicant wishes the start of the international preliminary examination to be postponed until the expiration of 20 months from the priority date unless the International Preliminary Examining Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). (This check-box may be marked only where the time limit under Article 19 has not yet expired.)

* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Language for the purposes of international preliminary examination: English



which is the language in which the international application was filed.



which is the language of a translation furnished for the purposes of international search.



which is the language of publication of the international application.



which is the language of the translation (to be) furnished for the purposes of international preliminary examination.

Box No. V ELECTION OF STATES

The applicant hereby elects all eligible States (that is, all States which have been designated and which are bound by Chapter II of the PCT)

excluding the following States which the applicant wishes not to elect:

1942-1943

Box No. VI CHECK LIST

The demand is accompanied by the following elements, in the language referred to in Box No. IV, for the purposes of international preliminary examination:

- | | | |
|--|---|----------|
| 1. translation of international application | : | sheets |
| 2. amendments under Article 34 | : | sheets |
| 3. copy (or, where required, translation) of amendments under Article 19 | : | sheets |
| 4. copy (or, where required, translation) of statement under Article 19 | : | sheets |
| 5. letter | : | 1 sheets |
| 6. other (<i>specify</i>) | : | sheets |

For International Preliminary Examining Authority use only

received	not received
----------	--------------

<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>

The demand is also accompanied by the item(s) marked below:

- | | |
|--|---|
| 1. <input checked="" type="checkbox"/> fee calculation sheet | 4. <input type="checkbox"/> statement explaining lack of signature |
| 2. <input type="checkbox"/> separate signed power of attorney | 5. <input type="checkbox"/> nucleotide and or amino acid sequence listing in computer readable form |
| 3. <input type="checkbox"/> copy of general power of attorney; reference number, if any: | 6. <input checked="" type="checkbox"/> other (<i>specify</i>): bank draft |

Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).

SIM & MCBURNEY

Patricia A. Rae (Dr.)

For International Preliminary Examining Authority use only

1. Date of actual receipt of DEMAND: JCC6 Rec'd PCT/PTO 19 JAN 2001

2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):

3. ☐ The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply.

☐ The applicant has been informed accordingly.

4. ☐ The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5.

5. ☐ Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.

For International Bureau use only

Demand received from IPEA on:

PCT

FEE CALCULATION SHEET

Annex to the Demand for international preliminary examination

<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">International application No.</td> <td style="width: 50%;">PCT/CA99/00656</td> </tr> <tr> <td>Applicant's or agent's file reference</td> <td>3206-172/PAR</td> </tr> </table>	International application No.	PCT/CA99/00656	Applicant's or agent's file reference	3206-172/PAR	<div style="border: 1px solid black; padding: 5px;"> For International Preliminary Examining Authority use only </div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> Date stamp of the IPEA </div>
International application No.	PCT/CA99/00656				
Applicant's or agent's file reference	3206-172/PAR				
Applicant HSC Research and Development Limited Partnership					
Calculation of prescribed fees					
1. Preliminary examination fee	<div style="border: 1px solid black; display: inline-block; padding: 2px 10px;">2,998.29</div> <div style="border: 1px solid black; display: inline-block; padding: 2px 5px; margin-left: 5px;">P</div>				
2. Handling fee (<i>Applicants from certain States are entitled to a reduction of 75% of the handling fee. Where the applicant is (or all applicants are) so entitled, the amount to be entered at H is 25% of the handling fee.</i>)	<div style="border: 1px solid black; display: inline-block; padding: 2px 10px;">287.51</div> <div style="border: 1px solid black; display: inline-block; padding: 2px 5px; margin-left: 5px;">H</div>				
3. Total of prescribed fees Add the amounts entered at P and H and enter total in the TOTAL box	<div style="border: 1px solid black; display: inline-block; padding: 2px 10px;">3,285.80</div>				
<div style="border: 1px solid black; display: inline-block; padding: 2px 10px;">TOTAL</div>					
Mode of Payment					
<input type="checkbox"/> authorization to charge deposit account with the IPEA (see below)	<input type="checkbox"/> cash				
<input type="checkbox"/> cheque	<input type="checkbox"/> revenue stamps				
<input type="checkbox"/> postal money order	<input type="checkbox"/> coupons				
<input checked="" type="checkbox"/> bank draft	<input type="checkbox"/> other (specify):				
Deposit Account Authorization (<i>this mode of payment may not be available at all IPEAs</i>)					
The IPEA/ _____ <input type="checkbox"/> is hereby authorized to charge the total fees indicated above to my deposit account.					
<input type="checkbox"/> (<i>this check-box may be marked only if the conditions for deposit accounts of the IPEA so permit</i>) is hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account.					
_____ Deposit Account Number	_____ Date (day/month/year)				
_____ Signature					

PATENT COOPERATION TREATY

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

09/744167

PCT

To:

RAE, Patricia A.
Sim & McBumey
330 University Avenue
6th floor
Toronto, Ontario M5G 1R7
CANADA

RECEIVED

SEP 22 2000

SIM & MCBURNEY
SIM, HUGHES, ASHTON & McKAY

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing (day/month/year)	19.09.2000
-------------------------------------	------------

Applicant's or agent's file reference 3206-172/PAR	IMPORTANT NOTIFICATION
---	-------------------------------

International application No. PCT/CA99/00656	International filing date (day/month/year) 20/07/1999	Priority date (day/month/year) 20/07/1998
---	--	--

Applicant

HSC RESEARCH AND DEVELOPMENT LIMITED ... et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.



Name and mailing address of the IPEA/	Authorized officer
<div style="display: flex; align-items: center;"> <div> <p>European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465</p> </div> </div>	<p>Vullo, C</p> <p>Tel. +49 89 2399-8061</p>



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 3206-172/PAR	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA99/00656	International filing date (day/month/year) 20/07/1999	Priority date (day/month/year) 20/07/1998
International Patent Classification (IPC) or national classification and IPC C12N15/12		
Applicant HSC RESEARCH AND DEVELOPMENT LIMITED ... et al.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 8 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none">I <input checked="" type="checkbox"/> Basis of the reportII <input type="checkbox"/> PriorityIII <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicabilityIV <input checked="" type="checkbox"/> Lack of unity of inventionV <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statementVI <input type="checkbox"/> Certain documents citedVII <input type="checkbox"/> Certain defects in the international applicationVIII <input checked="" type="checkbox"/> Certain observations on the international application		
Date of submission of the demand 17/02/2000	Date of completion of this report 19.09.2000	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Lanzrein, M Telephone No. +49 89 2399 7358 	



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA99/00656

I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

Description, pages:

1-62 as originally filed

Claims, No.:

1-44 as originally filed

Drawings, sheets:

1/20-20/20 as originally filed

2. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
☐ paid additional fees.
☐ paid additional fees under protest.
☐ neither restricted nor paid additional fees.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA99/00656

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
- 3: This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
- ☒ not complied with for the following reasons:

see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☒ all parts.
- ☐ the parts relating to claims Nos. .

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	3, 5, 9, 10, 21, 23, 24, 37-44
	No:	Claims	1, 2, 4, 6-8, 11-20, 22, 25-36
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-44
Industrial applicability (IA)	Yes:	Claims	1-44
	No:	Claims	

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item IV

Lack of unity of invention

Reference is made to the following documents:

- D1: B. MECKELEIN ET AL.: 'Identification of a novel serine protease-like molecule in human brain' MOL. BRAIN RESEARCH, vol. 55, no. 2, April 1998 (1998-04), pages 181-197. AMSTERDAM, NL & EMBL SEQUENCE DATABASE, 24 May 1999 (1999-05-24), Cambridge, UK
- D2: NAGASE T ET AL: 'Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro' DNA RESEARCH, JP, UNIVERSAL ACADEMY PRESS, vol. 4, no. 4, page 141-150. ISSN: 1340-2838 -& EMBL SEQUENCE DATABASE, 1 July 1997 (1997-07-01)

The application lacks unity within the meaning of Art. 34(3) and Rule 13.1 PCT. The separate inventions are:

- 1) human SARA1: claim 7, (completely); claims 1, 2, 4, 6, 11-19, 20, 22, 23, 25-44 (partially)
- 2) human SARA2: claim 8, (completely); claims 1, 2, 4, 6, 11-19, 20, 22, 23, 25-44 (partially)
- 3) Xenopus SARA1: claim 9 (completely); claims 1, 3, 5, 6, 11-19, 21, 24-44 (partially)
- 4) Xenopus SARA2: claim 10 (completely); claims 1, 3, 5, 6, 11-19, 21, 24-44 (partially)

They are not so linked as to form a single general inventive concept (Rule 13.1 PCT) for the following reasons: The four inventions concern four related proteins, two from human and two from Xenopus. Since the two human proteins are already known from D1 and D2 (see also reasoned statement below under item V), there is no common inventive concept which is new over the prior art.

All four inventions have been examined, the lack of unity notwithstanding. However, a

unity objection would most likely ensue in case of later entry into regional phases of the present application.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. The present application concerns Smad Anchor for Receptor Activation (SARA) proteins. The applicants provide the sequences of 2 human SARA proteins (hSARA1, hSARA2) and two from *Xenopus* (XSara1, XSara2). SARA proteins bind Smad signaling molecules and thereby recruit them into distinct subcellular domains. TGF β signaling induces dissociation of Smad2 from SARA and formation of Smad2/Smad4 complex. This complex translocates to the nucleus to regulate gene expression.
Claimed are the polynucleotide and protein sequences, antibodies, transgenic animals and various methods of treatment and of screening for allelic variants or candidate modulator compounds.
2. Claims 1, 2, 4, 6-8, 11-20, 22, 25-36 lack novelty according to Art. 33 (2) PCT.
 - 2.1 Claims 1, 2, 4, 6, 7, 11-20, 22, 25-36 are not new in view of D1. This document discloses cloning and expression of a novel serine protease (NSP). The cDNA sequence of NSP is identical to the hSARA1 sequence in Table 1 and, in consequence, the protein sequences are identical as well. The cDNA of NSP was recombinantly expressed in *E. coli* cells and purified via addition of a six histidine tag (p. 193, "3.5 Expression of recombinant..."). The purified protein was used to generate monoclonal antibodies (Fig. 6).
The disclosures in D1 are thus prejudicial to novelty of said claims.
We would like to emphasize that the functional features and functional domains which are included in some of the claims are in this case not relevant for assessment of novelty, because said functions are inherently present in the prior art molecule of D1. All claims concerned here are directed to a product which already existed. The existing product inherently possessed all the features even if



not disclosed explicitly.

In general, a claim to a substance or composition for a particular use should be construed as meaning a substance or composition which is in fact suitable for the stated use; a known product which is in fact suitable for the stated use, though it has never been described for that use is in fact prejudicial to novelty.

- 2.2 Claims 1, 2, 4, 6, 8, 11-16, 25-27 are not new in view of D2, cited by the applicant. D2 reports the isolation of 100 large cDNA inserts from a human brain library. The clone KIAA 305 (see Table 1, p. 145) is identical in sequence with the sequences of human SARA2 in Tables 3 and 4. This clone was transcribed/translated *in vitro* to confirm the size of the predicted ORF (Table 1). The above mentioned claims concern only the protein and DNA sequences and D2 is therefore prejudicial to novelty.
- 2.3 Claims 3, 5, 9, 10, 21, 23, 24, 37-44 are considered novel over the prior art in the sense of Art. 33 (2) PCT.
3. Claims 1, 3, 5, 6, 9-19, 21, 23-44 lack inventive step according to Art. 33 (3) PCT
- 3.1 Claims 1, 3, 5, 6, 9-19, 21, 24-44 concern the SARA proteins from *Xenopus*. For evaluation of inventiveness of the claims concerning the XSARA1 protein the closest prior art document is D1, which discloses the human sequence of SARA1. Correspondingly, for evaluation of inventiveness of the claims concerning XSARA2 the closest prior art is D2.
- The problem underlying the subject matter of the above claims could be seen in the provision of a further sequence of a SARA protein, which was solved by the provision of the *Xenopus* sequences. A person skilled in the art does not require any inventive skill for the cloning of the corresponding SARA sequences from *Xenopus*, especially when taking into account that it is general common knowledge that the corresponding human genes have high degrees of sequence similarity. Cloning of the *Xenopus* sequences with probes derived from the highly related human sequences is achieved by the mere use of standard techniques without undue difficulties and a high expectation of success.
- Moreover, it was known that the SARA proteins are expressed fairly ubiquitously *i.*



e. the activity was present in a variety of tissues. It was shown in D1 that NSP was expressed in all tissues investigated (Table 1). Also KIAA 305 was shown to be expressed in 10 out of 14 tissues investigated. This ubiquitous distribution points to an important role for those proteins in essential cellular processes, suggesting high conservation during evolution. It is therefore likely that said proteins are present not only in mammals but also in other more distant classes of organisms. Thus, indeed there was good reason to expect the presence of SARA homologues in *Xenopus*.

- 3.2 Claim 23 concerns the purified form of human SARA2 protein. The skilled person would, without exercise of inventive skill, purify said protein starting out from the cDNA sequence disclosed in D2. There are many standard techniques available to the person skilled in the art to perform such purification.
- 3.3 Claims 37-44 concern a catalogue of standard applications, which cannot be considered inventive since the SARA proteins representing the core of said applications are not novel and not inventive.

Re Item VIII

Certain observations on the international application

1. Claims 1-5, 12, 19-22, 29, 31, 33, 35-44 refer to a SARA protein. The protein or DNA is specified solely by a name which, however, is meaningless to the person skilled in the art. Although the protein was known in the prior art, it was given other names therein. It is therefore not clear what the subject matter is. In general, the technical feature characterizing a protein or DNA being a chemical product is the sequence.
2. Claims 12, 18, 19, 28-31, 33, 35 do not meet the requirements of Article 6 PCT with regard to clarity. Said claims refer to "functional domain", "fragment", or "substantially pure polypeptide". These terms are vague and unclear and leave the reader in doubt



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA99/00656

as to the meaning of the technical features to which they refer, thereby rendering the definition of the subject-matter of said claims unclear.

3. Claim 40 refers to methods for treatment of the human or animal body. In case of an European application this would not be allowable because said methods are not regarded as inventions which are susceptible of industrial application. However, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims.
4. In claim 43, claim L01 should probably read claim 42.

09/744167

1/4

PCT REQUEST

3206-172/PAR

Original (for SUBMISSION) - printed on 19.07.1999 03:09:29 PM

0	For receiving Office use only	
0-1	International Application No.	
0-2	International Filing Date	
0-3	Name of receiving Office and "PCT International Application"	
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using	PCT-EASY Version 2.83 (updated 01.03.1999)
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant)	Canadian Patent Office (RO/CA)
0-7	Applicant's or agent's file reference	3206-172/PAR
I	Title of invention	SARA PROTEINS
II	Applicant	
II-1	This person is:	applicant only
II-2	Applicant for	all designated States except US
II-4	Name	HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP
II-5	Address:	555 University Avenue Suite 5270 Toronto, Ontario M5G 1X8 Canada
II-6	State of nationality	CA
II-7	State of residence	CA
II-8	Telephone No.	416-813-5724
II-9	Facsimile No.	416-813-5085
III-1	Applicant and/or inventor	
III-1-1	This person is:	applicant and inventor
III-1-2	Applicant for	US only
III-1-4	Name (LAST, First)	WRANA, Jeffrey, L.
III-1-5	Address:	c/o HSC Research and Development Limited Partnership 555 University Avenue Suite 5270 Toronto, Ontario M5G 1X8 Canada
III-1-6	State of nationality	CA
III-1-7	State of residence	CA



PCT REQUEST

2/4

3206-172/PAR

Original (for SUBMISSION) - printed on 19.07.1999 03:09:29 PM

IV-1	Agent or common representative; or address for correspondence The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name (LAST, First)	RAE, Patricia, A.
IV-1-2	Address:	Sim & McBurney 330 University Avenue 6th Floor Toronto, Ontario M5G 1R7 Canada
IV-1-3	Telephone No.	416-595-1155
IV-1-4	Facsimile No.	416-595-1163
V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AP: GH GM KE LS MW SD SZ UG ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE CH&LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AL AM AT AU AZ BA BB BG BR BY CA CH&LI CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

PCT REQUEST

3206-172/PAR

Original (for SUBMISSION) - printed on 19.07.1999 03:09:29 PM

V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.		
V-6	Exclusion(s) from precautionary designations	NONE	
VI-1	Priority claim of earlier national application		
VI-1-1	Filing date	20 July 1998 (20.07.1998)	
VI-1-2	Number	2,237,701	
VI-1-3	Country	CA	
VI-2	Priority claim of earlier national application		
VI-2-1	Filing date	10 December 1998 (10.12.1998)	
VI-2-2	Number	2,253,647	
VI-2-3	Country	CA	
VI-3	Priority document request The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s):	VI-1, VI-2	
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)	
VIII	Check list	number of sheets	electronic file(s) attached
VIII-1	Request	4	-
VIII-2	Description	62	-
VIII-3	Claims	6	-
VIII-4	Abstract	1	abstract.txt
VIII-5	Drawings	20	-
VIII-7	TOTAL	93	
	Accompanying items	paper document(s) attached	electronic file(s) attached
VIII-8	Fee calculation sheet	✓	-
VIII-16	PCT-EASY diskette	-	diskette
VIII-18	Figure of the drawings which should accompany the abstract	18	
VIII-19	Language of filing of the international application	English	
IX-1	Signature of applicant or agent		
IX-1-1	Name (LAST, First)	RAE, Patricia, A.	

PCT REQUEST

3206-172/PAR

Original (for SUBMISSION) - printed on 19.07.1999 03:09:29 PM

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	JC06 Rec'd PCT/PTO 19 JAN 2001
10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

33

PCT (ANNEX - FEE CALCULATION SHEET)

3206-172/PAR

Original (for SUBMISSION) - printed on 19.07.1999 03:09:29 PM

(This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only		
0-1	International Application No.		
0-2	Date stamp of the receiving Office		
0-4	Form - PCT/RO/101 (Annex)		
0-4-1	PCT Fee Calculation Sheet Prepared using	PCT-EASY Version 2.83 (updated 01.03.1999)	
0-9	Applicant's or agent's file reference	3206-172/PAR	
2	Applicant	HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP, et al.	
12	Calculation of prescribed fees	fee amount/multiplier	total amounts (CAD)
12-1	Transmittal fee T	⇒	200
12-2	Search fee S	⇒	1,874
12-3	International fee Basic fee (first 30 sheets) b1	641	
12-4	Remaining sheets	63	
12-5	Additional amount (X)	15	
12-6	Total additional amount b2	945	
12-7	b1 + b2 = B	1,586	
12-8	Designation fees Number of designations contained in international application	79	
12-9	Number of designation fees payable (maximum 10)	10	
12-10	Amount of designation fee (X)	148	
12-11	Total designation fees D	1,480	
12-12	PCT-EASY fee reduction R	-220	
12-13	Total International fee (B+D-R) I	⇒	2,846
12-14	Fee for priority document Number of priority documents requested	1	
12-15	Fee per document (X)	0	
12-16	Total priority document fee P	⇒	0
12-17	TOTAL FEES PAYABLE (T+S+I+P)	⇒	4,920
12-19	Mode of payment	cheque	
12-20	Deposit account instructions The receiving Office:	Canadian Patent Office (RO/CA)	
12-20-2	is hereby authorized to charge any deficiency or credit any over-payment in the total fees indicated above to my deposit account	✓	
12-20-3	is hereby authorized to charge the fee for preparation and transmittal of the priority document to the International Bureau of WIPO to my deposit account	✓	

PCT (ANNEX - FEE CALCULATION SHEET)

3206-172/PAR

Original (for SUBMISSION) - printed on 19.07.1999 03:09:29 PM

12-21	Deposit account No.	00000
12-22	Date	19 July 1999 (19.07.1999)
12-23	Name and signature	RAE, Patricia, A.

VALIDATION LOG AND REMARKS

13-2-6	Validation messages Contents	Yellow! The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
13-2-7	Validation messages Fees	Green? Please confirm that fee schedule utilized is the latest available



Original (for SUBMISSION) - printed on 19.07.1999 03:09:29 PM

PCT-EASY INFORMATION SHEET

(For applicant use only, DO NOT submit this sheet with the international application)

VALIDATION LOG

Yellow!	Contents The power of attorney or a copy of the general power of attorney will need to be furnished unless all applicants sign the request form.
Green?	Fees Please confirm that fee schedule utilized is the latest available

Before submitting the International Application, please carefully verify that:

- the information contained on printed Request form is correct;
- Box IX of the Request form has been signed;
- all elements of the international application as indicated in Box VIII of the Request form have been attached; and,
- the diskette containing the PCT-EASY zip file of the International Application has been enclosed and has been clearly labeled "PCT-EASY", with the applicant's or agent's file reference, and the first applicant's name.

ATTENTION

DO NOT modify any indications on the Request form printout. The attached PCT-EASY application has been locked. If an error or an omission is discovered at this time, you must copy the submitted application as a template and make the change or correction in a new application (using the submitted application as a template). You may create such a template by copying the submitted application from the "Stored Forms" folder to the "New PCT Forms" folder. Open the new (.OWO) file created in the "New PCT Forms" folder, correct the errors and proceed with the submission process again.

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 3206-172/PAR	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/CA 99/ 00656	International filing date (day/month/year) 20/07/1999	(Earliest) Priority Date (day/month/year) 20/07/1998
Applicant HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☒ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☒ because the applicant failed to suggest a figure

☐ because this figure better characterizes the invention

18

☐ None of the figures.



INTERNATIONAL SEARCH REPORT

International Application No
CA 99/00656

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/12 C07K14/47 C12Q1/68 G01N33/50 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K C12Q G01N A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	B. MECKELEIN ET AL.: "Identification of a novel serine protease-like molecule in human brain" MOL. BRAIN RESEARCH, vol. 55, no. 2, April 1998 (1998-04), pages 181-197, XP000862820 AMSTERDAM, NL the whole document & EMBL SEQUENCE DATABASE, 24 May 1999 (1999-05-24), Cambridge, UK Accession no. EMHUM1:AF130419; ----- -/--	1,2,4, 6-8, 11-23, 25-36

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 December 1999

Date of mailing of the international search report

15/12/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hornig, H

INTERNATIONAL SEARCH REPORT

Inte: onal Application No

PCT/CA 99/00656

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NAGASE T ET AL: "Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro"</p> <p>DNA RESEARCH, JP, UNIVERSAL ACADEMY PRESS, vol. 4, no. 4, page 141-150-150</p> <p>XP002102085</p> <p>ISSN: 1340-2838</p> <p>the whole document</p> <p>-& EMBL SEQUENCE DATABASE,</p> <p>1 July 1997 (1997-07-01), XP002124759</p> <p>Cambridge, UK</p> <p>Accession no. EMHUM2.AB002303, KIAA0305</p>	<p>1,2,4,</p> <p>6-8,</p> <p>11-23,</p> <p>25-36</p>
A	<p>M. KRETZSCHMAR AND J: MASSAGUÉ: "SMADs: mediators and regulators of TGF-beta signaling"</p> <p>CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 8, no. 1, February 1998 (1998-02), pages 103-111, XP000857433</p> <p>CURRENT BIOLOGY LTD., PHILADELPHIA, US</p> <p>cited in the application</p> <p>the whole document</p>	
A	<p>E. LABBÉ ET AL.: "Smad2 and Smad3 positively and negatively regulate TGF-beta-dependent transcription through the forkhead DNA-binding protein FAST2"</p> <p>MOLECULAR CELL, vol. 2, no. 1, July 1998 (1998-07), pages 109-120, XP000857311</p> <p>CELL PRESS, CAMBRIDGE, MA, US</p> <p>cited in the application</p> <p>the whole document</p>	
P,X	<p>T. TSUKAZAKI ET AL.: "SARA, a FYVE domain protein that recruits Smad2 to the TGF-beta receptor"</p> <p>CELL, vol. 95, no. 6, 11 December 1998 (1998-12-11), pages 779-791, XP002124598</p> <p>CELL PRESS, CAMBRIDGE, MA, US;</p> <p>the whole document</p>	<p>1-36</p>

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/00656

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 38-40 (as far as in vivo methods are concerned) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 14 March 2000 (14.03.00)	
International application No. PCT/CA99/00656	Applicant's or agent's file reference 3206-172/PAR
International filing date (day/month/year) 20 July 1999 (20.07.99)	Priority date (day/month/year) 20 July 1998 (20.07.98)
Applicant WRANA, Jeffrey, L.	

1. The designated Office is hereby notified of its election made:


☒ in the demand filed with the International Preliminary Examining Authority on:

17 February 2000 (17.02.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).


The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Pascal Piriou Telephone No.: (41-22) 338.83.38
---	---





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, C12Q 1/68, G01N 33/50, A01K 67/027		A1	(11) International Publication Number: WO 00/05360
(21) International Application Number: PCT/CA99/00656		(43) International Publication Date: 3 February 2000 (03.02.00)	
(22) International Filing Date: 20 July 1999 (20.07.99)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data:			
2,237,701 20 July 1998 (20.07.98) CA 2,253,647 10 December 1998 (10.12.98) CA			
(71) Applicant (for all designated States except US): HSC RESEARCH AND DEVELOPMENT LIMITED PARTNERSHIP [CA/CA]; Suite 5270, 555 University Avenue, Toronto, Ontario M5G 1X8 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): WRANA, Jeffrey, L. [CA/CA]; HSC Research and Development Limited Partnership, Suite 5270, 555 University Avenue, Toronto, Ontario M5G 1X8 (CA). (74) Agent: RAE, Patricia, A.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).			

Published*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.***(54) Title:** SARA PROTEINS**(57) Abstract**

A new family of proteins, the SARA proteins, has been identified. These proteins bind to receptor-regulated Smad proteins and modulate signal transduction by TGF β , activin and bone morphogenetic protein.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Licchtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SARA PROTEINSField of the Invention

The invention relates to a family of proteins, the SARA proteins, which
5 bind to receptor-regulated Smad proteins and are involved in appropriate
localization of these Smad proteins for receptor activation.

Background of the Invention

The Transforming Growth Factor-beta (TGF β) superfamily, whose
10 members include TGF β s, activins and bone morphogenetic proteins (BMPs),
have wide ranging effects on cells of diverse origins (Attisano and Wrana, 1998;
Heldin et al., 1997; Kretzschmar and Massagué, 1998). Signaling by these
secreted factors is initiated upon interaction with a family of cell-surface
transmembrane serine/threonine kinases, known as type I and type II receptors.
15 Ligand induces formation of a type I/type II heteromeric complex which permits
the constitutively active type II receptor to phosphorylate, and thereby activate,
the type I receptor (Wrana et al., 1994). This activated type I receptor then
propagates the signal to a family of intracellular signaling mediators known as
Smads (Attisano and Wrana, 1998; Heldin et al., 1997; Kretzschmar and
20 Massagué, 1998).

The first members of the Smad family identified in invertebrates were the
Drosophila MAD and the *C. elegans* sma genes (sma-2, sma-3 and sma-4; Savage
et al., 1996; Sekelsky et al., 1995). Currently, the family includes additional
invertebrate Smads, as well as nine vertebrate members, Smad1 through 9
25 (Attisano and Wrana, 1998; Heldin et al., 1997; Kretzschmar and Massagué,
1998). Smad proteins contain two conserved amino (MH1) and carboxy (MH2)
terminal regions separated by a more divergent linker region. In general, Smad
proteins can be subdivided into three groups; the receptor-regulated Smads,
which include Smad 1, 2, 3, 5 and 8, Mad, sma-2 and sma-3; the common
30 Smads, Smad4 and Medea, and the antagonistic Smads, which include Smad6, 7

and 9, DAD and daf-3 (Heldin et al., 1997; Nakayama et al., 1998; Patterson et al., 1997).

Numerous studies with vertebrate Smad proteins have provided insights into the differential functions of these proteins in mediating signaling. Receptor-regulated Smads are direct substrates of specific type I receptors and the proteins are phosphorylated on the last two serines at the carboxy-terminus within a highly conserved SSXS motif (Abdollah et al., 1997; Kretzschmar et al., 1997; Liu et al., 1997b; Macias-Silva et al., 1996; Souchelnytskyi et al., 1997). Interestingly, Smad2 and Smad3 are substrates of TGF β or activin receptors and mediate signaling by these ligands (Liu et al., 1997b; Macias-Silva et al., 1996; Nakao et al., 1997a), whereas Smad1, 5 and 8 appear to be targets of BMP receptors and thereby propagate BMP signals (Chen et al., 1997b; Hoodless et al., 1995; Kretzschmar et al., 1997; Nishimura et al., 1998). Once phosphorylated, these Smads bind to the common Smad, Smad4, which lacks the carboxy-terminal phosphorylation site and is not a target for receptor phosphorylation (Lagna et al., 1996; Zhang et al., 1997). Heteromeric complexes of the receptor-regulated Smad and Smad4 translocate to the nucleus where they function to regulate the transcriptional activation of specific target genes. The antagonist Smads, Smad6, 7 and 9 appear to function by blocking ligand-dependent signaling by preventing access of receptor-regulated Smads to the type I receptor or possibly by blocking formation of heteromeric complexes with Smad4 (reviewed in Heldin et al., 1997).

Analysis of the nuclear function of Smads has demonstrated that Smads can act as transcriptional activators and that some Smads, including *Drosophila* Mad, and the vertebrate Smad3 and Smad4, can bind directly to DNA, albeit at relatively low specificity and affinity (Dennler et al., 1998; Kim et al., 1997; Labbé et al., 1998; Yingling et al., 1997; Zawel et al., 1998).

Localization of Smads is critical in controlling their activity and Smad phosphorylation by the type I receptor regulates Smad activity by inducing nuclear accumulation (Attisano and Wrana, 1998; Heldin et al., 1997; Kretzschmar and Massagué, 1998). However, little is known about how Smad

localization is controlled prior to phosphorylation and how this might function in modulating receptor interactions with its Smad substrates.

Summary of the Invention

5 Smad proteins (Smads) transmit signals from transmembrane ser/thr kinase receptors to the nucleus. Mammalian and non-mammalian proteins have been identified which interact directly with Smads and are designated the Smad Anchor for Receptor Activation or SARA proteins.

 The invention provides cDNA sequences encoding this previously
10 undescribed family of SARA proteins which bind to receptor-regulated Smad proteins and ensure appropriate localization of these Smad proteins for activation by a Type I receptor of a TGF β , activin or BMP signaling pathway.

 For example, TGF β signaling induces dissociation of Smad2 or Smad3 from a SARA protein with concomitant formation of Smad2/Smad4 or
15 Smad3/Smad4 complexes and nuclear translocation. In the absence of signaling, SARA functions to recruit a particular Smad (eg. Smad2 or Smad3) to distinct subcellular sites in the cell and interacts with the TGF β superfamily receptor complex in cooperation with the particular receptor regulated Smad. Mutations in hSARA1 that cause mislocalization of Smad2, and interfere with receptor
20 association, inhibit receptor-dependent transcriptional responses, indicating that regulation of Smad localization is essential for TGF β superfamily signaling. The invention provides a novel component of the signal transduction pathway that functions to anchor Smads to specific subcellular sites for activation by the Type I receptor of the TGF β , activin or BMP signaling pathways.

25 The SARA proteins are characterised by the presence of three domains, a double zinc finger or FYVE domain responsible for the subcellular localisation of the SARA protein or SARA-Smad complex, a Smad-binding domain which mediates the interaction or binding of one or more species of Smad protein and a carboxy terminal domain which mediates association with the TGF β
30 superfamily receptor. The FYVE domain may bind phosphatidyl inositol-3-phosphate.

In accordance with one embodiment, the invention provides isolated polynucleotides comprising nucleotide sequences encoding SARA proteins.

In accordance with a further series of embodiments, the invention provides an isolated polynucleotide selected from the group consisting of

- 5 (a) a nucleotide sequence encoding a human SARA protein;
- (b) a nucleotide sequence encoding a mammalian SARA protein;
- (c) a nucleotide sequence encoding a non-mammalian SARA protein;
- (d) a nucleotide sequence encoding the human SARA amino acid
10 sequence of Table 2 (hSARA1: Sequence ID NO:2);
- (e) a nucleotide sequence encoding the human SARA amino acid sequence of Table 4 (hSARA2: Sequence ID NO:4);
- (f) a nucleotide sequence encoding the *Xenopus* SARA amino acid sequence of Table 6 (XSARA1: Sequence ID NO:6);
- 15 (g) a nucleotide sequence encoding the *Xenopus* SARA amino acid sequence of Table 8 (XSARA2: Sequence ID NO:8).

In accordance with a further embodiment, the invention provides the nucleotide sequences of Table 1 (human SARA1 or hSARA1), Table 3 (human SARA2 or hSARA2), Table 5 (*Xenopus* SARA1 or XSARA1) and Table 7 (*Xenopus*
20 SARA2 or XSARA2).

In accordance with a further embodiment, the invention provides recombinant vectors including the polynucleotides disclosed herein and host cells transformed with these vectors.

The invention further provides a method for producing SARA proteins,
25 comprising culturing such host cells to permit expression of a SARA protein-encoding polynucleotide and production of the protein.

The invention also includes polynucleotides which are complementary to the disclosed nucleotide sequences, polynucleotides which hybridize to these sequences under high stringency and degeneracy equivalents of these
30 sequences.

In accordance with a further embodiment, the invention provides antisense molecules which may be used to prevent expression of a SARA protein. Such antisense molecules can be synthesised by methods known to those skilled in the art and include phosphorothioates and similar compounds.

5 The invention further includes polymorphisms and alternatively spliced versions of the disclosed SARA genes and proteins wherein nucleotide or amino acid substitutions or deletions do not substantially affect the functioning of the gene or its encoded protein.

10 The invention also enables the identification and isolation of allelic variants or homologues of the described SARA genes, and their corresponding proteins, using standard hybridisation screening or PCR techniques.

 The invention provides a method for identifying allelic variants or homologues of the described SARA genes, comprising

15 choosing a nucleic acid probe or primer capable of hybridizing to a SARA gene sequence under stringent hybridisation conditions;

 mixing the probe or primer with a sample of nucleic acids which may contain a nucleic acid corresponding to the variant or homologue; and

 detecting hybridisation of the probe or primer to the nucleic acid corresponding to the variant or homologue.

20 In accordance with a further embodiment, the invention provides fragments of the disclosed polynucleotides, such as polynucleotides of at least 10, preferably 15, more preferably 20 consecutive nucleotides of the disclosed polynucleotide sequences. These fragments are useful as probes and PCR primers or for encoding fragments, functional domains or antigenic determinants
25 of SARA proteins.

 In accordance with a further embodiment, the invention provides substantially purified SARA proteins, including the proteins of Table 2 (hSARA1), Table 4 (hSARA2), Table 6 (XSARA1) and Table 8 (XSARA2).

30 In accordance with one embodiment, a SARA protein has a FYVE domain, a Smad binding domain (SBD) and an amino acid sequence having at least 50% overall identity with the amino acid sequence of hSARA1 (Sequence ID NO:2).

In accordance with a preferred embodiment, a SARA protein has a FYVE domain having at least 65% identity of amino acid sequence with the FYVE domain of hSARA1 and a C-terminal sequence of 550 consecutive amino acids which have at least 50% identity with the C-terminal 550 amino acid residues of hSARA1.

In accordance with a more preferred embodiment, a SARA protein has a FYVE domain having at least 65% identity of amino acid sequence with the FYVE domain of hSARA1 and wherein the portion of the SBD corresponding to amino acid residues 721 to 740 of hSARA1 has at least 80% identity with that portion of hSARA1.

The invention further provides a method for producing antibodies which selectively bind to a SARA protein comprising the steps of administering an immunogenically effective amount of a SARA immunogen to an animal;

allowing the animal to produce antibodies to the immunogen; and obtaining the antibodies from the animal or from a cell culture derived therefrom.

The invention further provides substantially pure antibodies which bind selectively to an antigenic determinant of a SARA protein. The antibodies of the invention include polyclonal antibodies, monoclonal antibodies and single chain antibodies.

The invention includes analogues of the disclosed protein sequences, having conservative amino acid substitutions therein. The invention also includes fragments of the disclosed protein sequences, such as peptides of at least 6, preferably 10, more preferably 20 consecutive amino acids of the disclosed protein sequences.

The invention further provides polypeptides comprising at least one functional domain or at least an antigenic determinant of a SARA protein.

In accordance with a further embodiment, the invention provides peptides which comprise SARA protein Smad binding domains and polynucleotides which encode such peptides.

In accordance with a further embodiment, the invention provides a Smad binding domain peptide selected from the group consisting of

- (a) SASSQSPNPNNPAEYCSTIPPLQQAQASGALSSPPPTVMVPVGV
LKHPGAEVAQPREQRRVWFADGILPNGEVADAAKLTMNGTSS; and
- 5 (b) amino acids 589 to 672 of the XSARA1 sequence of Table 9.

The invention includes fragments and variants of these Smad binding domain peptides which retain the ability to bind a Smad protein.

In accordance with a further embodiment, the invention provides peptides which comprise SARA protein FYVE domains and polynucleotides
10 which encode such peptides.

In accordance with a further embodiment, the invention provides a FYVE domain peptide selected from the group consisting of

- (a) amino acids 587 to 655 of the hSARA1 sequence of Table 9;
- (b) amino acids 510 to 578 of the XSARA1 sequence of Table 9; and
- 15 (c) the consensus amino acid sequence of Table 10.

The invention includes fragments and variants of these FYVE domain peptides which retain the function of the parent peptide.

In accordance with a further embodiment, the invention provides peptides which comprise SARA protein TGF β receptor interacting domains and
20 polynucleotides which encode such peptides.

In accordance with a further embodiment, the invention provides a TGF β receptor interacting domain peptide comprising amino acids 751 to 1323 of the hSARA1 sequence of Table 9.

The invention includes fragments and variants of these TGF β receptor
25 binding domain peptides which retain the binding ability of the parent peptide.

The invention further provides methods for modulating signaling by members of the TGF β superfamily which signal through pathways which involve a SARA protein.

Modulation of signaling by a TGF β superfamily member through such a
30 pathway may be effected, for example, by increasing or reducing the binding of the SARA protein involved in the pathway with its binding partner.

In accordance with a further embodiment, TGF β superfamily signaling, including TGF β signaling, by a pathway involving a SARA protein described herein may be modulated by modulating the binding of the SARA protein to a Smad binding partner, by modulating the binding of its FYVE domain to its
5 binding partner or by modulating the binding of the SARA protein to a TGF β superfamily receptor, such as the TGF β receptor.

For example, the binding of a SARA protein to a Smad binding partner may be inhibited by a deletion mutant of the protein lacking either the SBD domain or the FYVE domain or by the SARA protein Smad binding domain
10 peptides or FYVE domain peptides described herein, and effective fragments or variants thereof. The binding of a SARA protein to a TGF β superfamily receptor may be inhibited by a deletion mutant of the protein lacking a C terminal portion or by the SARA protein TGF β receptor binding domain peptides described herein, and effective fragments and variants thereof.

15 In accordance with a further embodiment, TGF β superfamily signaling, including TGF β signaling, by a pathway involving a SARA protein may be modulated by modulating the binding of the SARA protein FYVE domain to phosphatidyl inositol-3-phosphate, by increasing or decreasing the availability of phosphatidyl inositol-3-phosphate or by administration of agonists or antagonists
20 of phosphatidyl inositol-3-phosphate kinase.

The invention also provides a method of modulating a TGF β superfamily signaling pathway involving phosphatidyl inositol-3-phosphate, including a TGF β signaling pathway, by increasing or decreasing the availability of SARA protein or by modulating the function of SARA protein.

25 The invention further provides methods for preventing or treating diseases characterised by an abnormality in a TGF β superfamily member signaling pathway which involves a SARA protein, by modulating signaling in the pathway, as described above.

TGF β signaling is important in wound healing, and excessive signaling is
30 associated with scarring, with arthritis and with fibrosis in numerous diseases, including fibrosis of the liver and kidney. TGF β signaling is also involved in

modulating inflammatory and immune responses and can contribute to tumour progression.

The invention thus provides methods for modulating TGF β -dependent cell proliferation or fibrogenesis.

5 The BMP signaling pathways are important in tissue morphogenesis and in protecting tissues and restoring or regenerating tissues after tissue damage, for example in bone, kidney, liver and neuronal tissue (see, for example, (Reddy, A.H. (1998), *Nature Biotechnology*, v. 16, pp. 247-252).

10 The invention further provides methods for modulating BMP-dependent phenotypic marker expression by modulating the interactions of SARA proteins involved in these BMP signaling pathways.

15 In accordance with a further embodiment, modified versions of a SARA protein may be provided as dominant-negatives that block TGF β superfamily signaling. These modified versions of SARA could, for example, lack the Smad binding domain and thereby prevent recruitment of Smad or could lack the FYVE domain and thereby inhibit signaling by interfering with translocation.

20 These modified versions of SARA may be provided by gene therapy, for example using transducing viral vectors. Expression may be driven by inclusion in the vector of a promoter specific for a selected target cell type. Many examples of such specific promoters are known to those skilled in the art.

 In a further embodiment, a normal version of a SARA protein such as hSARA1 could be provided by gene therapy to restore function in a disease wherein SARA is mutated or non-functional.

25 In a further embodiment, the invention provides a pharmaceutical composition comprising a purified SARA protein as active ingredient.

 In accordance with a further embodiment, the invention provides non-human transgenic animals and methods for the production of non-human transgenic animals which afford models for further study of the SARA system and tools for screening of candidate compounds as therapeutics. For example, knock
30 out animals, such as mice, may be produced with deletion of a SARA gene.

These animals may be examined for phenotypic changes and used to screen candidate compounds for effectiveness to reverse these changes.

In a further example, transgenic animals may be produced expressing a dominant negative mutant of a SARA protein, as described above, either
5 generally or in specific targeted tissues.

The invention provides many targets for the development of small molecule drugs, including peptides and peptidomimetic drugs, to interfere with the interaction of the various binding partners described herein and thereby modulate signaling by members of the TGF β superfamily, including TGF β and
10 BMPs.

The invention further provides methods for screening candidate compounds to identify those able to modulate signaling by a member of the TGF β superfamily through a pathway involving a SARA protein.

For example, the invention provides screening methods for compounds
15 able to bind to a SARA protein which are therefore candidates for modifying the activity of the SARA protein. Various suitable screening methods are known to those in the art, including immobilization of a SARA protein on a substrate and exposure of the bound SARA protein to candidate compounds, followed by elution of compounds which have bound to the SARA protein. The methods
20 used to characterise the binding interactions of the SARA proteins disclosed herein, as fully described in the examples herein, may also be used to screen for compounds which are agonists or antagonists of the binding of a SARA protein.

This invention also provides methods of screening for compounds which modulate TGF β superfamily signaling by detecting an alteration in the
25 phosphorylation state of a SARA protein.

In accordance with a further embodiment, the invention provides a method for reducing or preventing TGF β , activin or BMP signaling by inhibiting the activity of SARA. SARA activity may be inhibited by use of an antisense sequence to the SARA gene or by mutation of the SARA gene.

Summary of the Drawings

Certain embodiments of the invention are described, reference being made to the accompanying drawings, wherein:

Figure 1 (top panel) shows interaction of full length hSARA1 with
5 bacterially expressed Smads. Full length SARA protein was produced in an *in vitro* transcription/translation system in the presence of [³⁵S]methionine and was incubated with glutathione-sepharose beads coated with bacterially-expressed GST fusion proteins of the indicated Smads or Smad2 subdomains. Bound material was resolved by SDS-PAGE and visualized by autoradiography.
10 Migration of full length hSARA1, and a translation product that initiates from an internal methionine located upstream of the Smad binding domain (asterisk) are indicated. The presence of approximately equivalent amounts of GST fusion proteins was confirmed by SDS-PAGE and coomassie staining of a protein aliquot (bottom panel).

15 Figure 2 shows interaction of hSARA with Smads in mammalian cells. COS cells were transfected with Flag-tagged hSARA1 (Flag-SARA) either alone or together with the indicated Myc-tagged Smad constructs. For Smad6, an alternative version lacking the MH1 domain was used (Topper et al., 1997). Cell lysates were subjected to an anti-Flag immunoprecipitation and coprecipitating
20 Smads detected by immunoblotting with anti-Myc antibodies. The migration of anti-Flag heavy and light chains (IgG) are marked. To confirm efficient expression of hSARA1 and the Smads, aliquots of total cell lysates were immunoblotted with the anti-Flag and anti-Myc antibodies (bottom panel). The migrations of hSARA1 and the Smads are indicated.

25 Figures 3-6 show immunoblots of lysates from COS cells transiently transfected with various combinations of Flag or Myc-tagged hSARA1, wild type (WT) or mutant (2SA) Myc or Flag-tagged Smad2, Smad4/HA and wild type (WT) or constitutively active (A) TβRI/HA, cell lysates being subjected to immunoprecipitation with anti-Flag or anti-Myc antibodies, as indicated.
30 Confirmation of protein expression was performed by immunoblotting total cell

lysates prepared in parallel for the indicated tagged protein (totals, bottom panels).

Figure 3: Transfected cells were metabolically labelled with [32 P]PO₄ and cell lysates subjected to immunoprecipitation with anti-Flag antibodies for visualization of hSARA1 phosphorylation (top panel) or with anti-Myc antibodies for Smad2 phosphorylation (middle panel). Immunoprecipitates were resolved by SDS-PAGE and visualized by autoradiography. The migrations of hSARA1 and Smad2 are indicated.

Figure 4: Lysates from transiently transfected COS cells were subjected to immunoprecipitation with anti-Flag antibodies and Smad2 bound to hSARA1 was analyzed by immunoblotting with anti-Myc antibodies (IP: α -flag; blot: α -Myc).

Figure 5: Lysates from transiently transfected COS cells were subjected to immunoprecipitation with anti-Flag antibodies and Smad2 bound to hSARA1 was analyzed by immunoblotting with anti-Myc antibodies (IP: α -flag, blot: α -Myc). Partial dissociation of hSARA1/Smad2 complexes induced by TGF β signaling was enhanced by expression of Smad4.

Figure 6: Cell lysates from transiently transfected COS cells were subjected to immunoprecipitation with anti-Flag antibodies directed towards Smad2. Immunoprecipitates were then immunoblotted using anti-Myc or anti-HA antibodies which recognize hSARA1 or Smad4, respectively. Coprecipitating SARA (α -myc blot) and Smad4 (α -HA blot) are indicated.

Figure 7, panels A to E, shows photomicrographs of Mv1Lu cells transiently transfected with various combinations of Flag-Smad2, Myc-hSARA1, and constitutively active T β RI (T β RI*) as indicated (Tx). hSARA was visualized with the polyclonal Myc A14 antibody and Texas-Red conjugated goat-anti-rabbit IgG (red) and Smad2 was detected with an anti-Flag M2 monoclonal antibody followed by FITC-conjugated goat anti-mouse IgG (green). The subcellular localization of the expressed proteins was visualized by immunofluorescence and confocal microscopy.

Panels A, B, C, Mv1Lu cells singly transfected with hSARA1 (A) or Smad2 (B) are shown. Cotransfection of Smad2 with the constitutively active T β RI (T β RI*) results in its accumulation in the nucleus (C).

Panel D, Mv1Lu cells were transfected with hSARA1 and Smad2 and the
5 localization of hSARA1 (red, left photo) and Smad2 (green, centre photo) is shown. Colocalization of SARA and Smad2 is shown (right photo) and appears as yellow.

Panel E, Mv1Lu cells were transfected with hSARA1, Smad2 and activated
T β RI (T β RI*) and the localization of hSARA (red, left photo) and Smad2 (green,
10 centre photo) is shown. Colocalization of SARA and Smad2 is indicated (right photo). Note the shift to an orangy-red colour in the punctate spots and an intensification of Smad2 nuclear staining, indicative of dissociation of Smad2 from SARA and nuclear translocation.

Figure 7, panel F, shows photomicrographs of Mv1Lu cells stained with
15 rabbit, polyclonal anti-SARA antibody (left photo, green), goat, polyclonal anti-Smad 2/3 antibody (centre photo, red) and with both antibodies (right photo, yellow), showing co-localization of hSARA1 and Smad2.

Figure 8A shows photomicrographs of Mv1Lu cells transfected with either
hSARA1 alone (panel i), T β RII alone (panel ii) or hSARA1 and T β RII together
20 (panel iii), then treated with TGF β and the localization of hSARA1 (red) and T β RII (green) determined by immunofluorescence and confocal microscopy. In cells coexpressing hSARA1 and T β RII, superimposing the staining revealed colocalization of the proteins as indicated by yellow staining in panel iii.

Figure 8B shows affinity labelling of COS cells transiently transfected with
25 various combinations of Flag-hSARA1, Myc-Smad2, wild type (WT) T β RII and either wild type or kinase-deficient (KR) versions of T β RI. Cells were affinity-labelled with [125 I]TGF β and lysates immunoprecipitated with anti-Flag antibodies. Coprecipitating receptor complexes were visualized by SDS-PAGE and autoradiography. Equivalent receptor expression was confirmed by
30 visualizing aliquots of total cell lysates (bottom panel).

Figure 9A shows COS cells transiently transfected with wild type T β RII and kinase-deficient T β RI and various combinations of wild type Flag-hSARA1 (WT), a mutant version lacking the Smad2 binding domain (Δ SBD) and Myc-Smad2. The amount of receptor bound to SARA was determined by anti-Flag immunoprecipitation followed by gamma counting. Data is plotted as the average of three experiments \pm S.D. Protein expression was analyzed by immunoblotting aliquots of total cell lysates and the results from a representative experiment are shown (bottom panel).

Figure 9B shows COS cells transiently transfected with wild type T β RII and kinase-deficient T β RI and Flag-tagged wild type (WT) or mutant versions of hSARA1 with (black bars) or without (open bars) Myc-Smad2. The amount of receptor bound to hSARA1 was determined by anti-Flag immunoprecipitation followed by gamma counting. Protein expression was analyzed by immunoblotting aliquots of total cell lysates (bottom panel).

Figure 10 is a schematic representation of mutant versions of SARA. The FYVE domain (shaded bar) and the Smad binding domain, SBD (striped bar), are indicated. COS cells transiently transfected with Flag-hSARA1 and Myc-Smad2 were immunoprecipitated with anti-Flag antibodies followed by immunoblotting with anti-Myc antibodies. The presence (+) or absence (-) of a hSARA1/Smad2 interaction is indicated (Smad2 interaction). Mutants used for the subsequent localization study are marked on the left (i-vi).

Figure 11A shows an immunoblot of lysates from COS cells expressing Flag-tagged Smad2 or Smad3 incubated with GST alone or with GST-hSARA1 (665-750), which corresponds to the SBD; bound proteins were immunoblotted using anti-Flag antibodies. The presence of Smad2 and Smad3 bound to GST-hSARA1 (665-750) is indicated.

Figure 11B shows an immunoblot of lysates, from COS cells expressing Flag-tagged Smad2 together with wild type (WT) or activated (A) type I receptor, incubated with GST-hSARA1 (665-750) (GST-SBD) and immunoblotted with anti-Flag antibodies. The expression levels of Smad2, each receptor and GST-

hSARA1 (665-750) were determined by immunoblotting aliquots of total cell lysates.

Figure 12 shows the subcellular localization of hSARA1 mutants. Mv1Lu cells were transiently transfected with wild type (panel i) or mutant versions of Flag-hSARA1 (panels ii-viii, as marked on the left in Figure 10). Proteins were visualized by immunofluorescence and confocal microscopy using a monoclonal anti-Flag M2 monoclonal antibody followed by FITC-conjugated goat anti-mouse IgG.

Figure 13 shows photomicrographs of Mv1Lu cells transiently transfected with mutant versions of Myc-hSARA1 and Flag-Smad2 (panel A) or with wild type Myc-hSARA1, HA-Smad2 and mutant versions of hSARA1 (panel B). Protein subcellular localization was visualized by immunofluorescence and confocal microscopy. hSARA1 was visualized with the polyclonal Myc A14 antibody and FITC-conjugated goat anti-rabbit IgG (green), while Smad2 was detected with monoclonal antibodies followed by Texas Red-conjugated goat anti-mouse IgG (red). In B, overlaying the images reveals mislocalization of Smad2 as green speckles of SARA over red, diffuse Smad2 staining (panels ii and iii) and colocalization of hSARA1 and Smad2 appears as yellow spots (panels i and iv).

Figure 14 shows luciferase activity of Mv1Lu cells transfected with 3TP-lux alone or together with the indicated amounts of wild type (WT) or mutant (Δ 1-664 or Δ 1-704) versions of hSARA1 and incubated in the presence (black bars) or absence (open bars) of TGF β . Luciferase activity was normalized to β -galactosidase activity and is plotted as the mean \pm S.D. of triplicates from a representative experiment.

Figure 15 shows luciferase activity of HepG2 cells transfected with ARE-Lux alone (v), or ARE-Lux and FAST2 alone or together with the indicated amounts of wild type (WT) or mutant versions of hSARA1. Transfected cells were incubated in the presence (black bars) or absence (open bars) of TGF β and luciferase activity was normalized to β -galactosidase activity and is plotted as the mean \pm S.D. of triplicates from a representative experiment.

Figure 16 shows a Northern blot of expression of hSARA1 (upper panel) and Smad2 (lower panel) in the indicated tissues.

Figure 17 shows an immunoblot of a HepG2 lysate immunoprecipitated (IP) with preimmune serum (PI), anti-hSARA1 polyclonal antibody (SARA) with
5 and without pretreatment with TGF β (- and +), or N19 anti-Smad2/3 antibody (S2), followed by immunoblotting with an anti-Smad2 antibody. The migration position of Smad2 is indicated (Smad2).

Figure 18 shows a diagram of a model of the interaction of a SARA
10 protein with a receptor regulated Smad, as exemplified by the interaction of hSARA1.

Detailed Description of the Invention

This invention provides a family of proteins that play key roles in TGF- β , activin and bone morphogenetic protein (BMP) signal transduction pathways. In
15 particular, the proteins of this family interact with specific Smad proteins to modulate signal transduction. These proteins are therefore designated as "Smad Anchor for Receptor Activation" or "SARA" proteins. SARA proteins are characterised by three distinct domains (1) a double zinc finger or FYVE domain responsible for the subcellular localization of the SARA protein or SARA-Smad
20 complex, possibly through its association with PtdIns(3)P, (2) a Smad binding domain ("SBD") which mediates the interaction or binding of one or more species of Smad protein with the particular member of the SARA family and (3) a carboxy terminal domain which mediates interaction of SARA with members of the TGF β superfamily of receptors.

25 FYVE domains have been identified in a number of unrelated signaling molecules that include FGD1, a putative guanine exchange factor for Rho/Rac that is mutated in faciogenital dysplasia, the HGF receptor substrate Hrs-1 and its homolog Hrs-2, EEA1, a protein involved in formation of the early endosome and the yeast proteins FAB1, VPS27 and VAC1 (reviewed in Wiedemann and
30 Cockcroft, 1998). Recently, analysis of a number of FYVE domains from yeast and mammals has revealed that this motif binds phosphatidyl inositol-3-

phosphate (PtdIns(3)P) with high specificity and thus represents a novel signaling module that can mediate protein interaction with membranes (Burd and Emr, 1998; Gaullier et al., 1998; Patki et al., 1998; Simonsen et al., 1998; Wiedemann and Cockcroft, 1998). Comparison of the FYVE domains from the
5 vertebrate proteins with that from SARA revealed extensive conservation of residues throughout the domain (Table 10). Thus, SARA contains a FYVE domain that may function to bind PtdIns(3)P, which has been implicated in intracellular vesicle transport.

For example, deletion of the FYVE domain in hSARA1 causes
10 mislocalization of Smad2 or Smad3, interferes with TGF β receptor interaction and inhibits TGF β -dependent transcriptional responses.

Thus, the SARA proteins of the invention define a component of TGF β superfamily signaling that fulfills an essential role in anchoring receptor regulated Smads to specific subcellular domains for activation by a TGF β
15 superfamily receptor.

Cloned DNA coding sequences and corresponding amino acid sequences for representative human and Xenopus SARA protein family members are shown in the Tables, as follows:

Tables 1 and 2 – human SARA1 (hSARA1) cDNA (Sequence ID NO:1)
20 and amino acid sequence (Sequence ID NO:2) respectively;

Tables 3 and 4 – human SARA2 (hSARA2) cDNA (Sequence ID NO:3) and amino acid sequence (Sequence ID NO:4) respectively;

Tables 5 and 6 – Xenopus SARA1 (XSARA1) cDNA (Sequence ID NO:5) and amino acid sequence (Sequence ID NO:6) respectively; and

25 Tables 7 and 8 – Xenopus SARA2 (XSARA2) cDNA (Sequence ID NO:7) and amino acid sequence (Sequence ID NO:8) respectively.

Table 9 shows a comparison of the amino acid sequences of XSARA1 and hSARA1. Identical residues (dark grey) and conservative changes (light grey), the FYVE domain (solid underline) and the Smad binding domain (dashed
30 underline) are indicated. The sequences in XSARA1 used to design degenerate PCR primers for identifying hSARA1 are shown (arrows). The amino-terminal

end of the partial *Xenopus* cDNA obtained in the expression screen is marked (asterisk).

The human SARA of Tables 1 and 2, identified as described in Example 2, regulates the subcellular localization of Smad2 and Smad3 and recruits these
5 Smads into distinct subcellular domains. This SARA also interacts with TGF β receptors and TGF β signaling induces dissociation of Smad2 or Smad3 from the SARA protein with concomitant formation of Smad2/Smad4 complexes and nuclear translocation.

Table 10 shows alignment of the amino acid sequences of the FYVE
10 domains from hSARA1, XSARA1, KIAA0305, FGD1, Hrs-1, Hrs-2 and EEA1. Identical residues (dark grey) and conservative changes (light grey) are marked. A consensus sequence (bottom) was derived from positions in which at least 6 out of 7 residues were conserved or when proteins contained one of only two alternate residues.

15 The regulation of the subcellular localization of components of signaling pathways can be key determinants in the effective initiation and maintenance of signaling cascades. Targeting of signal transduction proteins to specific subcellular regions is highly regulated, often through specific interactions with scaffolding or anchoring proteins (Faux and Scott, 1996; Pawson and Scott,
20 1997). Scaffolding proteins have been defined as proteins that bind to multiple kinases to coordinate the assembly of a cascade, while anchoring proteins are tethered to specific subcellular regions in the cell and can act to bring together components of a pathway. Regulating location of signaling components can thus coordinate the activity of a signaling network, maintain signaling specificity
25 or facilitate activation of a pathway by localizing kinases together with their downstream substrates.

As described herein, a recombinantly produced human SARA protein bound directly and specifically to unphosphorylated Smad2 and Smad3. In addition, receptor-dependent phosphorylation induced Smad2 to dissociate from
30 SARA, bind to Smad4 and translocate to the nucleus. Thus, the hSARA1 protein functions in TGF β signaling upstream of Smad activation to recruit Smad2 to the

TGF β receptor by mediating the specific subcellular localization of Smad and by associating with the TGF β receptor complex. Furthermore, inducing mislocalization of Smad2 by expressing a mutant of the hSARA1 protein blocks TGF β -dependent transcriptional responses, indicating an essential role for SARA-mediated localization of Smads in signaling. Together, these results identify the cloned hSARA1 protein as a novel component of the TGF β pathway that functions to anchor Smad2 to specific subcellular sites for activation by the TGF β receptor kinase.

In vitro, receptor-regulated Smads are recognized by the receptor kinases and are phosphorylated on the C-terminal SSXS motif (Abdollah et al., 1997; Kretzschmar et al., 1997; Macias-Silva et al., 1996; Souchelnytskyi et al., 1997). This phosphorylation is similar to receptor-dependent phosphorylation in mammalian cells, suggesting that SARA is not absolutely required for recognition of Smads by the receptor complex. In intact cells, however, receptor-regulated Smads are cytosolic proteins that require activation by transmembrane serine/threonine kinase receptors. Consequently, Smads may require recruitment by SARA to interact with TGF β superfamily receptors. Domains in which SARA is found correspond to regions where TGF β receptors are also localised. TGF β receptors display regionalized localization and hSARA1 recruits Smad2 to these domains. The identity of these intracellular domains is unclear. However, they contain receptors and recent evidence has shown that FYVE finger domains interact with membranes, so it is reasonable to suggest that these domains represent membrane vesicles. Thus, clustering of the TGF β receptor, as previously described by Henis et al. (1994), may function to direct the receptor to hSARA1 and the Smad2 substrate. This activity may be most critical *in vivo*, where ser/thr kinase receptors are often found in low numbers and only a small proportion need to be activated for biological responses (Dyson and Gurdon, 1998). This activity is likely to be most critical *in vivo*, where ser/thr kinase receptors are often found in low numbers and only a small proportion need to be activated for biological responses (Dyson and Gurdon, 1998). This may impose

on the pathway a stringent requirement for SARA to anchor Smads in these sites for receptor interaction.

The colocalization and association of hSARA1 with the TGF β receptor defines a role for hSARA1 in recruiting Smad2 to the receptor kinase.

- 5 Furthermore, deletion of the FYVE domain interferes with receptor binding, prevents the correct localization of hSARA1/Smad2 and blocks TGF β signaling (see Example 8 below), suggesting that this is an important function in the pathway. Interestingly, the binding of the hSARA1 protein identified in Example 2 to the receptor was enhanced upon Smad2 expression and, on its own, SARA
10 may interact inefficiently with the receptor. However, within the hSARA1/Smad complex, Smad2 might help drive association with the receptor through its recognition of the catalytic region of the kinase domain. Consistent with this, cooperation requires a kinase deficient type I receptor which also traps the Smad2 substrate (Macías-Silva et al., 1996). Thus, Smad2 may bind to the
15 catalytic pocket of the type I kinase domain while hSARA1, which is not a substrate of the kinase, may interact with regions outside of the domain.

- The human SARA protein identified in Example 2 did not interact with any of the other Smads tested, indicating that it functions specifically in Smad2 and Smad3 pathways (see Example 3). However, Smad5 localization in
20 cells displayed a remarkably similar pattern to that of this SARA protein (Nishimura et al., 1998) and similar patterns were observed for endogenous Smad1 or 5 in the kidney epithelial cell line, IMCD-3. Thus, localization of BMP-regulated Smads (for example, Smad1, Smad5 and Smad8) may also be regulated by a specific SARA family member.

- 25 The genes for two other SARA family member proteins were also identified and cloned. One of these, identified in *Xenopus* and designated XSARA2 (Tables 7 and 8), is related to XSARA1, while the other one, hSARA2 (Tables 3 and 4), is a human clone, related to the hSARA1 of Tables 1 and 2. This second human clone has been identified in EST clone KIAA0305. A
30 comparison of the SBD from hSARA1 with a similar region from the KIAA0305 sequence indicated that the amino terminal half of the region of the SBD was

highly divergent from the amino acid sequence encoded by KIAA0305. This suggests that the protein encoded by KIAA0305 may mediate binding with other as yet unidentified proteins, eg. other Smads. In contrast to the SBD, the FYVE domain of the KIAA0305 protein is more closely related to the hSARA1 FYVE domain (70% identity), suggesting that this protein may be an anchor for other Smad proteins that function either in the TGF β pathway or in other signaling cascades, such as the BMP signal transduction pathway.

SARA is not limiting in Smad activation and TGF β superfamily signaling

It was observed that elevating Smad2 levels can saturate hSARA1 and yield a diffuse distribution for Smad2. Thus, the level of the hSARA1 protein is a key determinant in controlling Smad2 localization. As a consequence, endogenous Smad2 may or may not display a hSARA1-like distribution, depending on the relative expression of the two proteins. Indeed, in Mv1Lu cells, endogenous Smad2 displays a punctate pattern with some diffuse staining in the cytosol. While not meaning to limit the invention to a particular mechanism, the data are consistent with the view that once signaling has commenced, Smad2 dissociates from hSARA1, binds to Smad4 and translocates to the nucleus, freeing hSARA1 to recruit additional Smad2 from the cytosolic reservoir. This would provide a mechanism to allow quantitative activation of Smads in the presence of high levels of TGF β signaling.

By functioning to recruit Smad2 to the TGF β receptor, hSARA1 is located in an important regulatory position in the pathway. Thus, control of hSARA1 localization or protein levels, or its interaction with Smad2, could modulate TGF β signaling. Further, disruption of normal hSARA1 function could potentially be involved in loss of TGF β responsiveness that is a common feature during tumour progression.

Modular Domains in SARA

The function of hSARA1 in TGF β signaling is mediated by three independent domains, the Smad binding domain (SBD) that mediates specific

interaction with Smad2 and Smad3, the FYVE domain that targets hSARA1/Smad2 to specific subcellular sites and the carboxy terminus which mediates association with the TGF β receptor. The *Xenopus* and mouse forkhead-containing DNA binding proteins, FAST1 and FAST2, bind specifically to Smad2 and Smad3 and like hSARA1, interact with the MH2 domains (Chen et al., 1996; Chen et al., 1997a; Labbé et al., 1998; Liu et al., 1997a). Comparison of the SBD from this SARA with the Smad Interaction Domain (SID) from these FAST proteins revealed no regions of obvious similarity. However, since hSARA1 acts upstream and FAST downstream of Smad activation, these proteins may employ structurally unrelated domains to distinguish unactivated versus activated forms of Smad2. Thus, the SBD of this SARA protein preferentially binds unphosphorylated monomeric Smad2 while the SID from FAST must bind phosphorylated Smad2 in heteromeric complexes with Smad4. By analogy, the SBD of other SARA family members may bind the unphosphorylated monomeric species of other Smads that mediate signal transduction in other pathways (eg. Smads 1, 5 or 8 in the BMP signal transduction pathway).

In hSARA1, the FYVE domain functions independently of the SBD, to mediate the subcellular targetting of the protein. The FYVE-finger motif has now been identified in at least 30 proteins from diverse species, such as FGD1, Hrs-1 and 2, and EEA1 (Gaullier et al., 1998; Wiedemann and Cockcroft, 1998). Recent advances have demonstrated that FYVE finger motifs from a variety of divergent proteins have a conserved function and bind phosphatidyl inositol-3-phosphate (PtdIns(3)P) with high specificity (Burd et al., (1998); Patki (1998); Gaullier (1998)). Through this interaction, the FYVE finger can mediate protein interactions with phospholipid bilayers. However, PtdIns(3)P is present ubiquitously on cell membranes and in the case of EEA1, further protein-protein interactions with Rab5-GTP are required in addition to the FYVE domain to target the protein to the correct membranes (Simonsen et al., 1998). Given that PtdIns(3)P binding by FYVE fingers is conserved in yeast and mammals, it is likely that the FYVE finger of hSARA1 similarly mediates interaction with the

membrane. Furthermore, it is possible that additional protein-protein interactions may be required to direct hSARA1 to regions that contain the TGF β receptors. The carboxy terminus of hSARA1, which is required for efficient interaction with the TGF β receptor, may function in this capacity.

5 Together, these data define discrete domains in SARA that fulfill specific aspects of SARA function in TGF β superfamily signaling. Without being limited to any particular mechanism, a possible model of the interaction of SARA with a receptor regulated Smad in TGF β superfamily signaling, as exemplified by hSARA1 and its interactions with Smad2 in TGF β signaling, is shown
10 diagrammatically in Figure 18. The FYVE domain likely functions to direct SARA to the membrane, perhaps through interactions with PtlIns(3)P. It thus fulfills an important role in recruiting hSARA1 to specific subcellular domains that have been shown also to contain the TGF β receptor. The SBD in turn functions to bind unactivated Smad2, thus recruiting the receptor substrate to this subcellular
15 region. Once localized to this region, the C-terminal domain of hSARA1 functions with Smad2 bound to the SBD to promote interaction with the receptor complex. These three domains thus function cooperatively to recruit Smad2 to the TGF β receptor.

20 **Additional Roles for SARA**

Controlling the localization of kinases and their substrates may allow not only for efficient recognition and phosphorylation but may also function to maintain specificity and suppress crosstalk between signaling pathways. Thus, by controlling Smad localization, a SARA family member protein could
25 additionally function to maintain the highly specific regulation of Smad phosphorylation by ser/thr kinase receptors that is observed *in vivo* and could prevent promiscuous phosphorylation by other kinases in the cell. Furthermore, through its interactions with a particular receptor, a SARA protein might function to control the activity or turnover of the receptor complex. Alternatively, SARA
30 may also fulfill scaffolding functions to coordinate the receptor-dependent

activation of Smads with other as yet unidentified components of a signaling pathway.

Nucleic Acids

- 5 In accordance with one series of embodiments, the present invention provides isolated nucleic acids corresponding to, or related to, the human and Xenopus SARA nucleic acid sequences disclosed herein. In addition to the SARA nucleotide sequences disclosed herein, one of ordinary skill in the art is now enabled to identify and isolate homologues of the SARA genes described
- 10 herein. One of ordinary skill in the art may screen preparations of genomic or cDNA from other species using probes or PCR primers derived from nucleotide sequences disclosed herein. In accordance with a further embodiment, the invention provides isolated nucleic acids of at least 10 consecutive nucleotides, preferably 15 consecutive nucleotides, more preferably 20 consecutive
- 15 nucleotides of Sequences ID NO:1, Sequence ID NO:3, Sequence ID NO:5 and Sequence ID NO:7, up to the complete sequences. Short stretches of nucleotide sequence are useful as probes or primers useful for identification or amplification of the nucleic acids of the invention or for encoding fragments, functional domains or antigenic determinants of SARA proteins.
- 20 The invention also includes polynucleotides which are complementary to the disclosed sequences, polynucleotides which hybridise to these sequences at high stringency and degeneracy equivalents of these sequences.

Proteins

- 25 SARA proteins may be produced by culturing a host cell transformed with a DNA sequence encoding a selected SARA protein. The DNA sequence is operatively linked to an expression control sequence in a recombinant vector so that the protein may be expressed.

- 30 Host cells which may be transfected with the vectors of the invention may be selected from the group consisting of *E. coli*, *Pseudomonas*, *Bacillus*

subtillus, or other bacilli, yeasts, fungi, insect cells or mammalian cells including human cells.

For transformation of a mammalian cell for expression of a SARA protein, the vector may be delivered to the cells by a suitable vehicle. Such vehicles
5 including vaccinia virus, adenovirus, retrovirus, Herpes simplex virus and other vector systems known to those of skill in the art.

A SARA protein may also be recombinantly expressed as a fusion protein. For example, the SARA cDNA sequence is inserted into a vector which contains a nucleotide sequence encoding another peptide (e.g. GST-glutathione succinyl
10 transferase). The fusion protein is expressed and recovered from prokaryotic (e.g. bacterial or baculovirus) or eukaryotic cells. The fusion protein can then be purified by affinity chromatography based upon the fusion vector sequence and the SARA protein obtained by enzymatic cleavage of the fusion protein.

The protein may also be produced by conventional chemical synthetic
15 methods, as understood by those skilled in the art.

SARA proteins may also be isolated from cells or tissues, including mammalian cells or tissues, in which the protein is normally expressed.

The protein may be purified by conventional purification methods known to those in the art, such as chromatography methods, high performance liquid
20 chromatography methods or precipitation.

For example, anti-SARA antibodies may be used to isolate SARA protein which is then purified by standard methods.

Antibodies

25 The provision of the polynucleotide and amino acid sequences of SARA proteins provides for the production of antibodies which bind selectively to a SARA protein or to fragments thereof. The term "antibodies" includes polyclonal antibodies, monoclonal antibodies, single chain antibodies and fragments thereof such as Fab fragments.

30 In order to prepare polyclonal antibodies, fusion proteins containing defined portions or all of a SARA protein can be synthesized in bacteria by

expression of the corresponding DNA sequences, as described above. Fusion proteins are commonly used as a source of antigen for producing antibodies. Alternatively, the protein may be isolated and purified from the recombinant expression culture and used as source of antigen. Either the entire protein or
5 fragments thereof can be used as a source of antigen to produce antibodies.

The purified protein is mixed with Freund's adjuvant and injected into rabbits or other appropriate laboratory animals. Following booster injections at weekly intervals, the animals are then bled and the serum isolated. The serum may be used directly or purified by various methods including affinity
10 chromatography to give polyclonal antibodies.

Alternatively, synthetic peptides can be made corresponding to antigenic portions of a SARA protein and these may be used to inoculate the animals.

In a further embodiment, monoclonal anti-SARA antibodies may be produced by methods well known in the art. Briefly, the purified protein or
15 fragment thereof is injected in Freund's adjuvant into mice over a suitable period of time, spleen cells are harvested and these are fused with a permanently growing myeloma partner and the resultant hybridomas are screened to identify cells producing the desired antibody. Suitable methods for antibody preparation may be found in standard texts such as Antibody Engineering, 2d. edition,
20 Barreback, ED., Oxford University Press, (1995).

Transgenic animals

In accordance with a further embodiment, the invention provides for the production of transgenic non-human animals which afford models for further
25 study of the SARA family of proteins and also provide tools for the screening of the candidate compounds as therapeutics.

Animal species which are suitable for use include rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs and non-human primates.

In accordance with one embodiment, a transgenic animal may be
30 prepared carrying a heterologous SARA gene by inserting the gene into a germ line or stem cell using standard technique of oocyte microinjection, or

transfection or microinjection into embryonic stem cells. The techniques of generating transgenic animals are now well known and fully described in the literature. For example, a laboratory manual in the manipulation of the mouse embryo describes standard laboratory techniques for the production of transgenic mice (Hogan et al. (1986), Manipulating the Mouse Embryo, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, New York).

In accordance with a further embodiment, the invention enables the inactivation or replacement of an endogenous SARA gene in an animal by homologous recombination. Such techniques are also fully described in the literature. Such techniques produce "knock-out" animals, with an inactivated gene, or "knock-in" animals, with a replaced gene.

EXAMPLES

The examples are described for the purposes of illustration and are not intended to limit in any way the scope of the invention.

Methods of molecular genetics, protein and peptide biochemistry and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.

Example 1: Methods

Isolation of *Xenopus* and human SARA

To prepare a probe for library screening, the MH2 domain of Smad2 (amino acids 241-467) was subcloned into a modified pGEX4T-1 vector containing the protein kinase A recognition site derived from pGEX2TK (Pharmacia). This bacterial fusion protein was purified, labelled with [³²P]γATP and used as probe to screen a λZAP II *Xenopus* dorsal lip library as described (Chen and Sudol, 1995). A screen of 1 x 10⁶ plaques yielded four phage which represented repeated isolates of the same clone. This partial cDNA contained a 2.1 kb open reading frame and 1 kb of 3' untranslated region (UTR). A full length clone was obtained by a combination of rescreening of the same dorsal

lip library using a 670 base pair EcoRI/HpaI fragment at the 5' end of this clone and by 5' RACE (Gibco/BRL) using stage 10 *Xenopus* RNA.

- To obtain a human homolog of *Xenopus* SARA, cDNA was synthesized from randomly primed total RNA isolated from HepG2 cells. This cDNA was
- 5 subjected to polymerase chain reaction (PCR) using degenerate primers as described previously (Attisano et al., 1992). The 5' and 3' primers, designed to encode the zinc-finger motif, correspond to
- GC(A/C/G/T)CC(A/C/G/T)AA(C/T)TG(C/TATGAA(A/C/G/T)TG(C/T) and
(A/G)CA(A/G)TA(C/T)TC(A/C/G/T)GC(A/C/G/T)GG(A/G)TT(A/G)TT, respectively.
- 10 A 150 base pair PCR product was sequenced and then used as probe for screening a λ ZAP human fetal brain cDNA library (Stratagene). Eight positive plaques were obtained, two of which contained an overlap of approximately 1kb and covered the entire open reading frame. The sequence of the 5' UTR was confirmed by sequencing of an expressed sequence tag database clone (clone ID
- 15 260739).

Construction of Plasmids

- For mammalian expression constructs of SARA, the open reading frame of hSARA was amplified by PCR and was subcloned into pCMV5 in frame with an
- 20 amino-terminal Flag or Myc tag (Hoodless et al., 1996). The deletion mutants of pCMV5-Flag-hSara Δ 893-1323, Δ 346-132, Δ 893-1323, and Δ 346-1323 were constructed by deletion of EcoRV-HindIII, XbaI-HindIII, Sall-EcoRV, and Sall-XbaI fragments, respectively. pCMV5-Flag-hSara Δ 1-594 and Δ 1-686 were obtained by partial digestion with Asp718/Sall and for pCMV5-Flag-hSARA Δ 665-1323 a
- 25 Asp718/HindIII partial digest was used. pCMV5-Flag-hSARA Δ 596-704 was constructed by deleting Asp718 fragment. The other hSARA mutants were constructed by PCR using appropriate primers. pCMV5B-Myc-Smad3 and Myc-Smad6, pGEX4T-1-Smad2/MH1 (amino acids 1-181), pGEX4T-1-Smad2/linker (amino acids 186-273), pGEX4T-1-Smad2/MH2 (amino acids 241-467) and
- 30 pGEX4T-1-h SARA (amino acids 665-750) were constructed by PCR.

***In Vitro* Protein Interactions**

In vitro transcription/translation reactions were performed using the TNT coupled reticulocyte lysate system (Promega) following the manufacturer's instructions using T3 RNA polymerase. Translation was carried out in the presence of [³⁵S]-methionine and labelled proteins were incubated with purified GST fusion proteins in TNTE buffer with 10% glycerol for 2 hours at 4°C and then washed five times with the same buffer. Bound protein was separated by SDS-PAGE and visualized by autoradiography.

Immunoprecipitation and Immunoblotting

COS-1 cells transfected with LipofectAMINE (GIBCO BRL) were lysed with lysis buffer (Wrana et al., 1994) and subjected to immunoprecipitation with either anti-Flag M2 (IBI, Eastern Kodak) or anti-Myc (9E10) monoclonal antibody followed by adsorption to protein-G sepharose. Precipitates were separated by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted as described previously (Hoodless et al., 1996).

Affinity-Labeling

LipofectAMINE transfected COS-1 cells were incubated with 200 pM [¹²⁵I]TGFβ in media containing 0.2% bovine fetal serum at 37°C for 30 minutes and receptors were cross-linked to ligand with DSS as described previously (Macias-Silva et al., 1996). Cell lysates were immunoprecipitated with anti-Flag antibody and receptors visualized by SDS-PAGE and autoradiography. In some cases, cross-linked [¹²⁵I]TGFβ was determined by gamma counting.

25

Subcellular Localization by Immunofluorescent Confocal Microscopy

Mv1Lu cells, plated on gelatin-coated Permanox chamber slides (Nunc), were transfected by the calcium phosphate-DNA precipitation method. Fixation, permeabilisation and reaction with the primary and secondary antibodies were described previously (Hoodless et al., 1996). Monoclonal anti-Flag antibodies were visualized by FITC-conjugated goat anti-mouse IgG (Jackson Laboratories)

and polyclonal Myc antibody (A14, Santa Cruz) was visualized with Texas-Red-conjugated goat anti-rabbit IgG (Jackson Laboratories). Immunofluorescence was analyzed on a Leica confocal microscope.

5 **Transcriptional Response Assay**

Mv1Lu cells were transiently transfected with the reporter plasmid, p3TP-lux (Wrana et al., 1992), CMV- β gal and selected constructs using calcium phosphate transfection. Twenty-four hours after transfection, cells were incubated overnight with or without 50 pM TGF β . Luciferase activity was
10 measured using the luciferase assay system (Promega) in a Berthold Lumat LB 9501 luminometer and was normalized to β -galactosidase activity.

Example 2 - Identification of SARA family members

The MH2 domain of Smad2 was fused to glutathione-S-transferase (GST)
15 that included a kinase recognition site for protein kinase A (PKA). The bacterially-expressed fusion protein was labelled to high specific activity using PKA (Chen and Sudol, 1995), and then used to screen a λ ZAPII expression library prepared from the dorsal blastopore lip of *Xenopus*. From this screen,
20 four clones were identified, all of which presented a repeated isolate of a partial cDNA clone with no similarity to sequences in the GenBank database. To confirm that the product encoded by this clone interacted with Smad2, an *in vitro* transcription/translation system was used to produce [35 S]methionine-labelled protein. Translation of the cDNA yielded a protein product of
25 approximately 80 kDa which corresponded in size to the longest open reading frame (ORF) identified in the sequence. Incubation of this product with bacterially-produced GST-Smad2(MH2) resulted in efficient binding of the translated product to the fusion protein (data not shown). Interaction with full length Smad2 was also observed, whereas binding to bacterially-expressed Smad1 or Smad4 was not.

30 To isolate a full length cDNA, the partial clone identified in the interaction screen was used as a probe to rescreen the same blastopore lip

library. Since the resulting clones lacked the 5' end, 5' RACE was conducted to obtain the entire coding sequence. Analysis of the complete cDNA sequence (Table 5) revealed a long open reading frame that was contiguous with that of the partial clone. The predicted protein, XSARA1, is 1235 amino acids long with an estimated molecular mass of 135 kDa (Table 6). Analysis of the full length cDNA sequence (Table 9) revealed a region in the middle portion of the predicted protein that had similarity to a double zinc finger domain (recently renamed the FYVE domain; Mu et al., 1995). The FYVE domain has been identified in a number of unrelated signaling molecules that include FGD1, a putative guanine exchange factor for Rho/Rac that is mutated in faciogenital dysplasia (Pasteris et al., 1994), the HGF receptor substrate Hrs-1 and its homolog Hrs-2 (Bean et al., 1997; Komada and Kitamura, 1995), EEA1, a protein involved in formation of the early endosome (Mu et al., 1995) and the yeast proteins FAB1, VPS27 and VAC1 (Piper et al., 1995; Weisman and Wickner, 1992; Yamamoto et al., 1995). Comparison of the FYVE domains from the vertebrate proteins with that from SARA revealed extensive conservation of residues throughout the domain (Table 10). Thus, SARA contains a FYVE domain that may fulfill important functions in diverse proteins.

To investigate the role of SARA in TGF β superfamily signaling in mammalian cells, a human homologue was identified. Using a carboxy-terminal portion of XSARA1, a human library was screened and a protein was identified that was distantly related to *Xenopus* SARA (34% identity) and which was also sequenced as an EST (KIAA0305). However, no homologs closer to XSARA were identified. Thus, degenerate oligonucleotide primers were designed encoding amino acids in XSARA1 (Table 9) and HepG2 RNA was used as template for degenerate PCR. A related sequence was identified and this partial cDNA was used to screen a human brain cDNA library. Four overlapping clones, encoding a long open reading frame were identified and a search of the EST database with this sequence led to the identification of additional overlapping cDNA clones from libraries derived from T cells, uterus, endothelial cells and melanocytes. Analysis of the contiguous sequence revealed a long

open reading frame that had a consensus start codon preceded by stop codons in all three reading frames (Table 1). Comparison of the predicted protein hSARA1 (Table 2), from this cDNA with XSARA1 (Table 9) revealed an overall identity of 62%, with a divergent 558 residue amino terminal domain (35% identity) followed by a closely related carboxy terminus (85% identity).

Example 3 - hSARA interacts specifically with Smad2 and Smad3

To characterize the interaction of hSARA with Smads, the full length protein was translated *in vitro* and tested for binding to bacterially-expressed Smad fusion proteins. Similar to the *Xenopus* clone, hSARA1 bound specifically to full length Smad2, but not Smad1 or Smad4 (Figure 1). In addition, full length Smad3, which is highly related to Smad2, also interacted with hSARA1. To define the domains of Smad2 that bound hSARA, in bacteria various fragments of Smad2 corresponding to the MH1 domain, linker region and MH2 domain were expressed in bacteria. Similar to the *Xenopus* clone, hSARA interacted efficiently with fusion proteins that comprised the MH2 domain, while no association was detected between hSARA and either the MH1 or non-conserved linker domains (Figure 1). Thus, hSARA1 specifically interacts with Smad2 through the MH2 domain.

To confirm that hSARA also bound to Smads in mammalian cells, a Flag epitope tag was introduced at the amino terminus of the protein to create Flag-SARA. Transient expression of Flag-SARA in COS cells yielded a protein of the predicted molecular weight for SARA (Figure 2) that was not present in untransfected cells (data not shown). To investigate the interaction of SARA with Smads, Flag-SARA was expressed in COS cells together with Myc-tagged versions of Smads 1, 2, 3, 4, 6 and 7. Cell lysates were subjected to anti-Flag immunoprecipitation followed by immunoblotting with anti-Myc antibodies. In other immunoprecipitates of cells expressing either Smad2 or Smad3, efficient coprecipitation of either Smad with Flag-hSARA1 was observed (Figure 2). In contrast, none of the other Smads coprecipitated with hSARA1. Specific binding of this SARA family member to both Smad2 and Smad3 is consistent with the

observation that these two proteins possess very closely related MH2 domains (97% identity) and are both activated by TGF β or activin type I receptors (Liu et al., 1997b; Macias-Silva et al., 1996; Nakao et al., 1997a). Together, these results demonstrate that this SARA family member is a specific partner for
5 receptor-regulated Smads of the TGF β /activin signaling pathway.

Example 4- Phosphorylation of Smad2 induces dissociation from SARA

Previous findings have shown that activation of TGF β signaling results in phosphorylation of Smad2 or Smad3 by type I receptors on C-terminal serine
10 residues (Liu et al., 1997b; Macias-Silva et al., 1996). A constitutively active TGF β type I receptor was prepared by substituting a threonine in the GS domain with an aspartate residue (Wieser et al., 1995). This activated type I receptor induces TGF β signaling in the absence of type II receptors and ligand and regulates the phosphorylation and activation of Smad proteins in a manner
15 similar to ligand (Macias-Silva et al., 1996; Wieser et al., 1995). COS cells were transfected with combinations of Smad2, hSARA1 or both in the presence or absence of activated T β RI. Cells were then metabolically labelled with [32 P]phosphate and phosphorylation of either hSARA1 or Smad2 was assessed in immunoprecipitates. Analysis of SARA phosphorylation revealed that the protein
20 was basally phosphorylated and the coexpression of the activated type I receptor did not appreciably affect the overall phosphorylation (Figure 3). In contrast, analysis of Smad2 immunoprecipitated from total cell lysates showed that the activated type I receptor induced strong phosphorylation of the protein as described previously (Macias-Silva et al., 1996). These results suggest that SARA
25 is not phosphorylated in response to TGF β signaling.

The phosphorylation state of Smad2 that coprecipitated with hSARA1 was examined. Interestingly, unlike the strong induction of Smad2 phosphorylation in the total cellular pool, phosphorylation of Smad2 associated with hSARA1 was not enhanced, but rather appeared to decrease in the presence of TGF β signaling
30 (Figure 3). This suggested that receptor-dependent phosphorylation of Smad2 might induce dissociation from hSARA1. To examine this directly, the

interaction of hSARA1 with wild type Smad 2 or a mutant version lacking the C-terminal phosphorylation sites (Smad2(2SA)) was analysed. In the absence of TGF β signaling, association of hSARA1 with either Smad2 or Smad2(2SA) was comparable (Figure 4). In contrast, in cells coexpressing the activated receptor, a significant decrease in the interaction of wild type Smad2 with hSARA1 was observed. However, hSARA1/Smad2(2SA) complexes were not reduced by the activated receptor. Together, these results suggest that hSARA1 is not phosphorylated in response to TGF β signaling and that it preferentially interacts with the unphosphorylated form of Smad2.

10

Example 5 - SARA and Smad4 form mutually exclusive complexes with Smad2

Phosphorylation of Smad2 induces its interaction with Smad4 (Lagna et al., 1996; Zhang et al., 1997). hSARA1/Smad2 complexes in COS cells coexpressing Smad4 were assessed. In unstimulated cells, the level of hSARA1/Smad2 complex formation was comparable either in the presence or absence of Smad4 (Figure 5, lanes 3 and 6). However, upon activation of TGF β signaling, dissociation of Smad2 from hSARA1 was significantly enhanced by coexpression of Smad4 (Figure 5, lanes 4 and 7). These results indicated that phosphorylated Smad2 might preferentially interact with Smad4 rather than hSARA1 and suggested that Smad2 might form mutually exclusive complexes with either Smad4 or hSARA1. The formation of Smad2/Smad4 and Smad2/hSARA4 complexes in the same transfectants was then examined. Cell lysates were subjected to immunoprecipitation with anti-Flag antibodies directed towards tagged Smad2 and then immunoblotted for the presence of Smad4 and hSARA1. Consistent with previous findings (Lagna et al., 1996; Zhang et al., 1997), interaction of Smad4 with Smad2 was strongly stimulated by the activated type I receptor (Figure 6, lane 3 and 4). Concomitant with the formation of Smad2/Smad4 complexes, the interaction of Smad2 with hSARA1 was disrupted by activation of signaling (Figure 6, lanes 6 and 7). Thus, complexes of Smad2/hSARA1 and Smad2/Smad4 are mutually exclusive, supporting the notion that Smad4 may compete for Smad2 to enhance dissociation of hSARA1/Smad2

complexes. Together these results demonstrate that during TGF β signaling, hSARA1/Smad2 complexes are transient and phosphorylation of Smad2 induces dissociation and formation of heteromeric complexes with Smad4.

5 **Example 6- hSARA1 regulates the subcellular localization of Smad2**

The studies described above suggest that SARA functions upstream in the pathway and might control the subcellular localization of Smad2. To test this, an investigation was done to determine whether coexpression of hSARA1 might alter the localization of Smad2 in the TGF β -responsive epithelial cell line, Mv1Lu, using confocal microscopy. Mv1Lu cells were used rather than COS since the Myc antibodies crossreacted with endogenous proteins in the COS and obscured nuclear staining of tagged proteins. In cells expressing hSARA1 alone, the protein displayed a punctate staining pattern that was present throughout the cytosolic compartment and was excluded from the nucleus (Figure 7A). This localization of hSARA1 was in contrast to the diffuse staining typically observed for Smad2 in cells overexpressing the protein (Figure 7B). Cells transiently transfected with both hSARA1 and Smad2 were examined. In these cells, the distribution of hSARA1 was indistinguishable from cells transfected with hSARA1 alone (Figure 7D, left photo). In contrast, the localization of Smad2 in the presence of hSARA1 displayed a dramatic shift to a punctate pattern (compare Figure 7B to 7D, centre photos). Moreover, analysis of these immunofluorescent staining patterns by confocal microscopy revealed that hSARA1 and Smad2 precisely colocalized in the cytosol (yellow stain, Figure 7D, right photo). Interestingly, expression of Smad2 at much higher levels than hSARA1 reverted the distribution of Smad2 to that observed in cells transfected with Smad2 alone (data not shown). This supports the notion that elevating the amount of Smad2 can saturate hSARA1 and yield a diffuse distribution of Smad2 throughout the cell.

Studies were conducted to determine whether activation of TGF β signaling induces nuclear translocation of Smad2 in the presence of hSARA1. As shown in Figure 7, the localization of hSARA1 in the cytosolic compartment

looked similar in the presence or absence of the constitutively active TGF β type I receptor (compare Figure 7D and E, left photos). However, TGF β signaling caused a significant proportion of Smad2 to translocate to the nucleus (Figure 7E, centre photo) and this correlated with a shift to an orangy-red colour in the
5 cytosolic colocalization stain (Figure 7E, right photo). Thus activation of TGF β signaling induces Smad2 to dissociate from hSARA1 and translocate to the nucleus.

To confirm that the punctate localization of overexpressed SARA reflected that of the endogenous protein, the localization of endogenous SARA and Smad2
10 was examined in Mv1Lu cells. Analysis of the distribution of endogenous hSARA1 using affinity-purified rabbit anti-hSARA1 antibodies revealed a punctate distribution that was similar to the pattern observed for transiently transfected, epitope-tagged hSARA1 (Figure 7F, left photo). This staining was specific, since cells stained with preimmune antisera, or purified antibody
15 blocked with the hSARA1 antigen, revealed no detectable staining in the cytosol, although some weak background staining was observed in the nucleus (data not shown). Examination of endogenous Smad2 distribution in the same cell using goat anti-Smad2 antibodies revealed a punctate distribution for Smad2 (Figure 7F, centre photo) as published previously (Janknecht et al., 1998). Furthermore,
20 analysis of hSARA1 and Smad2 together revealed extensive colocalization of the two proteins (Figure 7F, right photo). Colocalization was not complete and may reflect differences in the stoichiometry of hSARA1 versus Smad2 protein levels as suggested above, or the presence of additional regulatory mechanisms in the cell that control interaction of the endogenous proteins.

25 Taken together with the biochemical analysis, these results indicate that hSARA1 functions to anchor or recruit Smad2 to specific subcellular regions prior to activation by TGF β signaling.

Example 7 - hSARA1 co-localises with T β RII

30 The positioning of hSARA1 upstream of Smad2 activation suggested to us that hSARA1 might recruit Smad2 to specific subcellular domains for

phosphorylation and activation by the receptor. Interestingly, previous studies on the TGF β receptor demonstrated clustering of the receptor complex into punctate domains that resembled those displayed by hSARA1 (Henis et al., 1994). To test whether hSARA1 might colocalize with TGF β receptors, the subcellular localization of hSARA1 and TGF β Mv1Lu receptors was investigated in Mv1Lu cells. Endogenous TGF β receptors could not be detected, likely due to the low numbers of TGF β receptors present on these cells and the even fewer number that are activated in the presence of ligand. The localization of hSARA1 in Mv1Lu cells cotransfected with T β RII and treated with TGF β was therefore examined. In the absence of hSARA1, T β RII displayed a punctate staining pattern similar to the hSARA1 pattern (Figure 8A, panels i and ii, respectively), as observed previously in COS cells. Furthermore, in cells coexpressing hSARA1 and TGF β receptors, extensive colocalization of hSARA1 and T β RII was observed (Figure 8A, panel iii). This colocalization was not complete. This may be due to a restricted distribution of hSARA1 in only a subset of the intracellular compartments normally occupied by transmembrane receptors, which include the endoplasmic reticulum, Golgi and endocytic pathways. Thus, hSARA1 and the TGF β receptors colocalize to common subcellular domains.

The colocalization of hSARA1 and the TGF β receptors suggested the possibility that hSARA1 may interact with the TGF β receptor. To test this, a strategy was utilised similar to that employed to characterize the interaction of Smad2 with the TGF β receptor (Macías-Silva et al., 1996). Briefly, COS cells were cotransfected with TGF β receptors in the presence of hSARA1 and were affinity-labelled using [125 I]TGF β . hSARA1 was then immunoprecipitated from the cell lysates and coprecipitating receptor complexes were resolved by SDS-PAGE and visualized by autoradiography or were quantitated using a gamma counter. Analysis of cells expressing wild type receptors type II and type I, revealed that receptor complexes coprecipitated with hSARA1 (Figure 8B, lane 3). Furthermore, in the presence of kinase deficient type I receptor, there was a small increase in binding of hSARA1 to the receptor (Figure 8B, lane 2). This is in contrast to Smad2, which only interacts with TGF β receptor complexes that

contain kinase deficient type I receptors (Macías-Silva et al., 1996). These data suggest that hSARA1 associates with the TGF β receptor.

Next examined was whether coexpression of Smad2 might enhance the interaction of hSARA1 with TGF β receptors. In cells expressing wild type
5 receptor I, no difference in the amount of receptor complexes that coprecipitated with hSARA1, either in the presence or absence of Smad2, was observed (Figure 8B, compare lanes 3 and 5). In contrast, the association of hSARA1 with receptor complexes containing kinase-deficient type I receptors was enhanced by Smad2 (Figure 8B, lane 4). This finding was consistent with the previous
10 demonstration that kinase-deficient type I receptors stabilize interactions of Smad2 with the receptors. To investigate further the requirement for Smad2 in the interaction of hSARA1 with the receptor, a mutant of hSARA1, SARA(Δ SBD), that removes the Smad binding domain, was tested. Analysis of wild type hSARA1 interaction with receptor complexes containing kinase-deficient T β RI
15 showed that wild type hSARA1 interacted with the receptor and this was enhanced approximately two-fold by Smad2 (Figure 9A). The Δ SBD mutant of hSARA1 retained the capacity to associate with the receptor, although the efficiency of interaction was slightly reduced relative to wild type hSARA1. Importantly, unlike wild type hSARA1, binding of mutant hSARA1 to the
20 receptor was not enhanced by coexpression of Smad2. Together, these data suggest that hSARA1 interacts with the TGF β receptor independently of Smad2 binding and that Smad2 cooperates to enhance the association.

To further characterize the domains in SARA that mediate binding to the TGF β receptor, the interaction of a panel of SARA mutants with the TGF β
25 receptor was tested. Interestingly, interaction with the TGF β receptor was strongly suppressed in three mutants in which the FYVE domain was disrupted (Figure 9B; Δ 594, Δ 664 and the internal deletion Δ 597-665). Since the FYVE domain is required for the correct subcellular localization of SARA, it was postulated that, once bound to the membrane, other regions in SARA might
30 contribute to the interaction with the receptor. To examine this possibility, several carboxy-terminal truncation mutants of hSARA1 were tested.

Interestingly, deletion of the C-terminus downstream of position 750 suppressed receptor interaction, despite efficient expression of the truncated protein. This suggests that regions in the carboxy-terminus of SARA contribute to receptor interaction. In these analyses, the question of whether overexpression of Smad2 could rescue some interaction of SARA mutants with the receptor was also explored. For both the FYVE domain mutants and the C-terminal truncation, Smad2 expression was able to restore some interaction with the TGF β receptor. It is likely that the high levels of protein and receptor expression that are achieved in COS cells can drive some receptor interaction, even in the absence of appropriate localization signals.

Example 8 - A modular domain in SARA mediates association with Smads

To investigate the functional importance of SARA in TGF β signaling, the domains in the protein that mediate both its localization to specific subcellular regions and its interaction with Smad2 were defined. To this end, a series of deletion mutants of hSARA1 were constructed and tested for their ability to interact with Smad2 in COS cells by immunoprecipitation followed by immunoblotting. As summarized in Figure 10, loss of the first 665 amino acids of hSARA1, which included the double zinc finger/FYVE domain, did not interfere with hSARA1 binding to Smad2. However, further deletions (Δ 1-704) completely abolished the interaction of Smad2 with hSARA1. To map the carboxy-terminal boundary of the Smad binding domain, a number of C-terminal truncations were also analyzed. Deletion of all residues downstream of position 750 did not affect Smad2 interaction with hSARA1, while an additional loss of 85 amino acids (Δ 665-1323) completely abrogated binding to Smad2. To determine whether the region defined by this deletional analysis was sufficient to bind Smad2, the 85 amino acids referred to as the Smad Binding Domain (SBD) were linked to GST and the fusion protein was expressed in bacteria (GST-h SARA(665-750)). Incubation of lysates prepared from cells expressing Smad2 or Smad3 with GST-SBD resulted in efficient binding of both Smads to the fusion protein (Figure 11A). This interaction is likely direct, since bacterially expressed

SBD associates efficiently with bacterially-produced Smad2 (data not shown). These studies thus define a novel domain in SARA that mediates interaction with Smad2 and Smad3 and which is located downstream of the FYVE domain.

The above-described analysis in COS cells showed that phosphorylation
5 of Smad2 by the TGF β receptor induced dissociation from SARA. To determine whether this reflects an alteration in the ability of the SBD to bind phosphorylated Smad2, the interaction of GST-SBD with Smad2 in lysates obtained from cells expressing Smad2 alone, or Smad2 together with either wild type or activated TGF β type I receptor, was tested. As described previously,
10 coexpression of activated type I receptors with the appropriate receptor-regulated Smad yields efficient phosphorylation of Smad protein. In lysates from cells expressing Smad2 alone or Smad2 with wild type receptors, efficient binding of Smad2 to GST-SBD was observed. In contrast, in the presence of activated T β RI, the interaction of Smad2 with GST-SBD was strongly reduced
15 (Figure 11B). This reduction correlated with receptor-dependent phosphorylation, since the phosphorylation site mutant, Smad2(2SA), interacted efficiently with GST-SBD, even in the presence of activated T β RI (data not shown). These data strongly support a mechanism whereby SARA interacts with unphosphorylated Smad2 and receptor-dependent phosphorylation induces
20 dissociation by altering the affinity of Smad2 for the SBD.

Example 9 - The FYVE domain controls the subcellular localization of SARA

The subcellular localization of a selection of the SARA mutants was analysed by immunofluorescence and confocal microscopy. Analysis of
25 truncation mutants that removed the amino terminus upstream of the FYVE domain (Δ 1-531) yielded wild type patterns of staining (Figure 12, compare panels i and ii). However, a further deletion (Δ 1-664) that disrupted the FYVE domain but did not interfere with the Smad binding domain, abolished the wild type staining pattern (Figure 12, panel iii). Similar studies of the C-terminal
30 domains showed that residues downstream of the FYVE domain (Δ 665-1323) did not alter the localization of the mutant protein (Figure 12, panel iv), while

truncations within the FYVE domain ($\Delta 596-1323$) led to diffuse localization throughout the cell (Figure 12, panel v). Of note, the $\Delta 665-1323$ mutant lacked the Smad binding domain, thereby indicating that interaction with Smad2 is not required for proper SARA localization. To confirm that FYVE domain function was required for localization of SARA, a mutant with a small internal deletion that removes the FYVE domain ($\Delta 597-664$) was tested. Consistent with the other mutants, localization of this protein was clearly disrupted (Figure 12, panel vi). Since none of these mutants interfered with Smad binding, the FYVE domain appears to be required to maintain the normal localization of SARA but is not involved in mediating interactions with Smads.

Example 10 - SARA-mediated localization of Smad2 is necessary for TGF β signaling

The availability of mutants of hSARA1 that interact with Smad2 but fail to target to the appropriate subcellular sites allowed the question of whether hSARA1-mediated localization of Smad2 was important to TGF β signaling to be addressed. Whether SARA($\Delta 1-594$) and SARA($\Delta 1-664$), which bind Smad but fail to distribute to the correct subcellular domains, would mislocalize Smad2 was examined. Coexpression of either mutant with Smad2 showed that they were unable to recruit Smad2 to the normal SARA domains (Figure 13A, panels i and ii). As expected, SARA($\Delta 1-704$), which lacks a Smad binding domain, was unable to control Smad2 localization (Figure 13A, panel iii). Whether these mutants could cause mislocalization of Smad2 was also examined. For this, cells were cotransfected with wild type hSARA1 and Smad2 either in the absence or presence of SARA($\Delta 1-594$), SARA($\Delta 1-664$) or SARA($\Delta 1-704$). In control transfectants, performed in the absence of mutant hSARA1, hSARA1 and Smad2 were colocalized in punctate domains as described above (Figure 13B, panel i). However, in the presence of either SARA($\Delta 1-594$) or SARA($\Delta 1-664$), the localization of wild type hSARA1 was normal, but the distribution of Smad2 was clearly disrupted and displayed a diffuse pattern (Figure 13B, panels ii and iii, respectively). Moreover, coexpression of SARA($\Delta 1-704$), which does not

bind Smad2, resulted in Smad2 distribution that was indistinguishable from that of the wild type pattern (Figure 13B, panel iv). Thus, SARA(Δ 1-594) and SARA(Δ 1-664) induce the mislocalization of Smad2.

Since SARA(Δ 1-664) mislocalizes Smads and interferes with receptor association, we investigated whether this mutant would disrupt TGF β signaling. To test this, we transiently transfected the TGF β -responsive reporter gene 3TP-lux into Mv1Lu cells in the presence and absence of wild type or mutant versions of hSARA1. Expression of wild type hSARA1 had no effect on TGF β signaling (Figure 14). In contrast, transfection of SARA(Δ 1-664) significantly inhibited TGF β -dependent signaling at the lowest concentration of DNA tested, while transfection of higher doses completely abolished responsiveness of the cells. We also tested SARA(Δ 1-704) which lacks a functional Smad binding domain and does not alter Smad2 localization. Transfection of this mutant had no effect on TGF β signaling (Figure 14). In addition to analysis of the 3TP promoter, we examined induction of the activin response element (ARE) from the *Xenopus* Mix.2 gene in HepG2 cells.

This ARE is stimulated by either TGF β or activin signaling, which induces assembly of a DNA binding complex that is composed of Smad2, Smad4 and a member of the FAST family of forkhead DNA binding proteins. Since HepG2 cells do not possess endogenous FAST activity, wild type or mutants of hSARA1 were cotransfected with FAST2 and the ARE-lux reporter plasmid as described previously (Labbé et al., 1998). Expression of either SARA(1- Δ 594) or SARA(1- Δ 664), which interfere with or delete the FYVE domain, respectively, resulted in a strong suppression of TGF β -dependent induction of the ARE (Figure 15). However, none of the other mutants tested suppressed activation of this promoter. Since none of these latter mutants disturb the localization of hSARA1-Smad2 complexes, these data strongly suggest that recruitment of Smad2 to the receptor-containing subcellular domains is important for TGF β signaling.

30 Example 11 - Tissue distribution of hSARA expression

The 3'UTR of hSARA1 and a Smad2 cDNA fragment were used to probe a human multiple tissue Northern blot (Clontech). The results are shown in Figure 16 - hSARA1: upper panel and Smad2: lower panel. hSARA1 and Smad2 were ubiquitously expressed in the tissues examined; relatively low levels of hSARA1 were selected in liver. hSARA1 and Smad2 showed a similar expression pattern except in placenta, where proportionally more Smad2 message was observed. A single transcript of 5.0 kb is seen, corresponding to the full length hSARA1 cDNA.

SARA expression was examined in a variety of cell lines using RT-PCR analysis and the gene was found to be expressed in every cell line tested. These included HepG2 hepatoma cells, NBFL neuroblastoma cells, SW480 colorectal cancer cells, N1H 3T3 fibroblasts, P19 embryonic carcinoma cells, MC3T3 calvarial cells and Mv1Lu lung epithelial cells (data not shown). hSARA1 appears to be a ubiquitously expressed partner for Smad2 and Smad3.

15

Example 12 - Interaction of endogenous hSARA1 and Smad2 in mammalian cells

Lysates from HepG2 cells, either untreated or treated with InM TGF β , were immunoprecipitated with an affinity-purified, anti-hSARA1 rabbit polyclonal antibody and the immunoprecipitates were immunoblotted with a polyclonal, anti-Smad2 antibody (Macias-Silva et al., 1998). Controls were immunoprecipitated with pre-immune sera or N19 anti-Smad2/3 antibody. The results are shown in Figure 17. In immunoprecipitates prepared with preimmune antisera, no Smad2 was detectable. Anti-hSARA1 immunoprecipitates clearly showed Smad2 co-precipitating with hSARA1. TGF β treatment prior to lysis gave decreased association of Smad2 and SARA.

25

These results demonstrate that SARA is a specific partner of receptor-regulated Smads in the TGF β /activin signaling pathway and further suggest that TGF β signaling induces dissociation of SARA/Smad complexes.

The present invention is not limited to the features of the embodiments described herein, but includes all variations and modifications within the scope of the claims.

REFERENCES

- Abdollah, S., Macías-Silva, M., Tsukazaki, T., Hayashi, H., Attisano, L., and Wrana, J.L. (1997). T β RI phosphorylation of Smad2 on Ser 465 and 467 is required for Smad2/Smad4 complex formation and signaling. *J. Biol. Chem.* 272, 27678-27685.
- Attisano, L. and Wrana, J.L. (1998). Mads and Smads in TGF β signaling. *Curr. Op. Cell Biol.* 10, 188-194.
- Attisano, L., Wrana, J.L., Cheifetz, S., and Massagué, J. (1992). Novel activin receptors: Distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. *Cell* 68, 97-108.
- Bean, A.J., Siefert, R., Chen, Y.A., Sacks, R., and Scheller, R.H. (1997). Hrs-2 is an ATPase implicated in calcium-regulated secretion. *Nature* 385, 826-829.
- Burd et al., (1998), *Mol. Cell.*, 2, 157-162.
- Chen, H.I. and Sudol, M. (1995). The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. *Proc Natl Acad Sci USA* 82, 7819-7823.
- Chen, X., Rubock, M.J., and Whitman, M. (1996). A transcriptional partner for MAD proteins in TGF- β signaling. *Nature* 383, 691-696.
- Chen, X., Weisberg, E., Fridmacher, V., Watanabe, M., Naco, G., and Whitman, M. (1997a). Smad4 and FAST-1 in the assembly of activin-responsive factor. *Nature* 389, 85-89.
- Chen, Y., Bhushan, A., and Vale, W. (1997b). Smad8 mediates the signaling of the receptor serine kinase. *Proc. Natl. Acad. Sci. USA* 94, 12938-12943.
- Chen, Y., Lebrun, J.-J., and Vale, W. (1996). Regulation of transforming growth factor β - and activin-induced transcription by mammalian Mad proteins. *Proc. Natl. Acad. Sci. USA* 93, 12992-12997.
- Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., and Gauthier, J.-M. (1998). Direct binding of Smad3 and Smad4 to critical TGF β -inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO J.* 17, 3091-3100.
- Dyson, S. and Gurdon, J.B. (1998). The Interpretation of Position in a Morphogen Gradient as Revealed by Occupancy of Activin Receptors. *Cell* 93, 557-568.

- Faux, M. and Scott, J.D. (1996). Molecular glue: kinase anchoring and scaffold proteins. *Cell* 85, 9-12.
- 5 Gaullier et al., (1998), *Nature*, 394, 433-434.
- Heldin, C.-H., Miyazono, K., and ten Dijke, P. (1997). TGF- β signaling from cell membrane to nucleus through SMAD proteins. *Nature*. 390, 465-471.
- 10 Henis, Y.I., Moustakas, A., Lin, H.Y., and Lodish, H.F. (1994). The type II and III transforming growth factor- β receptors form homo-oligomers. *J. Cell Biol.* 126, 139-154.
- 15 Hoodless, P.A., Haerry, T., Abdollah, S., Stapleton, M., O'Connor, M.B., Attisano, L., and Wrana, J.L. (1996). MADR1, a MAD-related protein that functions in BMP2 signaling pathways. *Cell* 85, 489-500.
- Janknecht et al., (1998), *Genes & Development*, 12, 2114-2119.
- 20 Kim, J., Johnson, K., Chen, H.J., Carroll, S., and Laughon, A. (1997). *Drosophila* Mad binds to DNA and directly mediates activation of *vestigial* by decapentaplegic. *Nature* 388, 304-308.
- 25 Komada, M. and Kitamura, N. (1995). Growth factor-induced tyrosine phosphorylation of Hrs, a novel 115-kilodalton protein with a structurally conserved putative zinc finger domain. *Mol Cell Biol* 15, 6213-6221.
- 30 Kretzschmar, M., Liu, F., Hata, A., Doody, J., and Massagué, J. (1997). The TGF- β family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. *Genes Dev.* 11, 984-995.
- 35 Kretzschmar, M. and Massagué, J. (1998). SMADs: mediators and regulators of TGF- β signaling. *Current Opinion in Genetics & Development* 8, 103-111.
- 40 Labbé, E., Silvestri, C., Hoodless, P.A., Wrana, J.L., and Attisano, L. (1998). Smad2 and Smad3 positively and negatively regulate TGF β -dependent transcription through the forkhead DNA binding protein, FAST2. *Molecular Cell* in press.
- 45 Lagna, G., Hata, A., Hemmati-Brivanlou, A., and Massagué, J. (1996). Partnership between DPC4 and SMAD proteins in TGF- β signaling pathways. *Nature* 383, 832-836.
- Liu, F., Poupponnot, C., and Massagué, J. (1997a). Dual role of the Smad4/DPC4 tumor suppressor in TGF β -inducible transcriptional complexes. *Genes & Development* 11, 3157-3167.

Liu, X., Sun, Y., Constantinescu, S.N., Karam, E., Weinberg, R.A., and Lodish, H.F. (1997b). Transforming growth factor β -induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in
5 epithelial cells. *Proc. Natl. Acad. Sci. USA* 94, 10669-10764.

Macías-Silva, M., Abdollah, S., Hoodless, P.A., Pirone, R., Attisano, L., and Wrana, J.L. (1996). MADR2 is a substrate of the TGF β receptor and its phosphorylation is required for nuclear accumulation and signaling. *Cell* 87,
10 1215-1224.

Mu, F.T., Callaghan, J.M., Steele-Mortimer, O., Stenmark, H., Parton, R.G., Campbell, P.L., McCluskey, J., Yeo, J.P., Tock, E.P., and Toh, B.H. (1995). EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical
15 peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. *J Biol Chem* 270, 13503-13511.

Nakao, A., Imamura, T., Souchelnytskyi, S., Kawabata, M., Ishisaki, A., Oeda, E., Tamaki, K., Hanai, J.-i., Heldin, C.-H., Miyazono, K., and ten Dijke, P.
20 (1997a). TGF- β receptor-mediated signaling through Smad2, Smad3 and Smad4. *EMBO J.* 16, 5353-5362.

Nakao, A., Röijer, E., Imamura, T., Souchelnytskyi, S., Stenman, G., Heldin, C.-H., and ten Dijke, P. (1997b). Identification of Smad2, a human Mad-related protein in the transforming growth factor β signaling pathway. *J. Biol. Chem.* 272, 2896-2900.
25

Nakayama, T., Snyder, M.A., Grewal, S.S., Tsuneizumi, K., Tabata, T., and Christian, J.L. (1998). *Xenopus* Smad8 acts downstream of BMP-4 to modulate its activity during vertebrate embryonic patterning. *Development* 125,
30 857-867.

Nishimura, R., Kato, Y., Chen, D., Harris, S.E., Mundy, G.R., and Yoneda, T. (1998). Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. *J. Biol. Chem.* 273, 1872-1879.
35

Pasteris, N.G., Cadle, A., Logie, L.J., Porteous, M.E., Schwartz, C.E., Stevenson, R.E., Glover, T.W., Wilroy, R.S., and Gorski, J.L. (1994). Isolation and characterization of the facio-genital dysplasia (Aarskog-Scott syndrome) gene: a putative Rho/Rac guanine nucleotide exchange factor. *Cell* 79, 669-678.
40

Patki et al., (1998), *Nature*, 394, 433-4.

45 Patterson, G., Koweeck, A., Wong, A., Liu, Y., and Ruvkun, G. (1997). The DAF-3 Smad protein antagonizes TGF- β -related receptor signaling in the *C. elegans* dauer pathway. *Genes and Dev.*

- Pawson, T. and Scott, J.D. (1997). Signaling through scaffold, anchoring and adaptor proteins. *Science* 278, 2075-2080.
- 5 Piper, R.C., Cooper, A.A., Yang, H., and Stevens, T.H. (1995). VPS27 controls vacuolar and endocytic traffic through a prevacuolar compartment in *Saccharomyces cerevisiae*. *J Cell Biol* 131, 603-617.
- 10 Savage, C., Das, P., Finelli, A., Townsend, S., Sun, C., Baird, S., and Padgett, R. (1996). The *C. elegans sma-2, sma-3* and *sma-4* genes define a novel conserved family of TGF- β pathway components. *Proc. Natl. Acad. Sci. USA* 93, 790-794.
- 15 Sekelsky, J.J., Newfeld, S.J., Raftery, L.A., Chartoff, E.H., and Gelbart, W.M. (1995). Genetic characterization and cloning of Mothers against dpp, a gene required for decapentaplegic function in *Drosophila melanogaster*. *Genetics* 139, 1347-1358.
- 20 Simonsen et al., (1998), *Nature*, 394, 494-495.
- Souchelnytskyi, S., Tamaki, K., Engström, U., Wernstedt, C., ten Dijke, P., and Heldin, C.-H. (1997). Phosphorylation of Ser⁴⁶⁵ and Ser⁴⁶⁷ in the C Terminus of Smad2 Mediates Interaction with Smad4 and Is Required for Transforming Growth Factor- β Signaling. *J. Biol. Chem.* 272, 28107-28115.
- 25 Topper, J.N., Cai, J., Qiu, Y., Anderson, K.R., Xu, Y.-Y., Deeds, J.D., Feeley, R., Gimeno, C.J., Woolf, E.A., Tayber, O., Mays, G.G., Sampson, B.A., Schoen, F.J., Gimbrone, M.A.J., and Falb, D. (1997). Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. *Proc. Natl. Acad. Sci. USA* 94, 9314-9319.
- 30 Weisman, L.S. and Wickner, W. (1992). Molecular characterization of VAC1, a gene required for vacuole inheritance and vacuole protein sorting. *J Biol Chem* 267, 618-623.
- 35 Wiedemann et al., (1998), *Nature*, 394, 426-427.
- 40 Wieser, R., Wrana, J.L., and Massague, J. (1995). GS domain mutations that constitutively activate T β R-I, the downstream signaling component in the TGF- β receptor complex. *EMBO J.* 14, 2199-2208.
- 45 Wrana, J.L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X.-F., and Massagué, J. (1992). TGF- β signals through a heteromeric protein kinase receptor complex. *Cell* 71, 1003-1014.
- Wrana, J.L., Attisano, L., Wieser, R., Ventura, F., and Massague, J. (1994). Mechanism of activation of the TGF- β receptor. *Nature* 370, 341-347.

- 5 Yamamoto, A., DeWald, D.B., Boronenkov, I.V., Anderson, R.A., Emr, S.D., and Koshland, D. (1995). Novel PI(4)P 5-kinase homologue, Fab1p, essential for normal vacuole function and morphology in yeast. *Mol Biol Cell* 6, 525-539.
- 10 Yingling, J.M., Datto, M.B., Wong, C., Frederick, J.P., Liberati, N.T., and Wang, X.-F. (1997). Tumour Suppressor Smad4 is a Transforming Growth Factor β -Inducible DNA Binding Protein. *Mol. Cell. Biol.* 17, 7019-7028.
- Zawel, L., Dai, J.L., Buckhaults, P., Zhou, S., Kinzler, K.W., Vogelstein, B., and Kern, S.E. (1998). Human Smad3 and Smad4 are sequence-specific transcription activators. *Mol. Cell* 1, 611-617.
- 15 Zhang, Y., Musci, T., and Derynck, R. (1997). The tumor suppressor Smad4/DPC4 as a central mediator of Smad function. *Curr. Biol.* 7, 270-276.

TABLE 1 - hSRA1 - Sequence ID NO:1

GCATACTGAATCAGCAGGACTGGCTGGTGGTGCAGCAGACATCATGAGTAAGCACC GA
GAAGTCTGTTCCCTTATCACGTGTGTAAGGGGAAAAAGGTTTAAACAAGTCTCTTAAGT
GGTGTTCCTCACCGATGGAGAATTACTTCCAAGCAGAAGCTTACAACCTGGGACAAG
GTGTTAGATGAATTTGAACAAAACGAAGATGAAACAGTTTCTTCTACTTTATTGGATA
CAAAGTGGAATAAGATTCTAGATCCCCCTTCTCACCGGCTGTCAATTAACCCTACTTT
GGCCAGTGTGAATGAATCTGCAGTTTCTAATGAGTCACAACCACAACCTGAAAGTCTTC
TCCCTGGCTCATTAGCTCCCCCTGACCACAGAGGAAGAGGATCACTGTGCTAATGGAC
AGGACTGTAATCTAAATCCAGAGATTGCCACAATGTGGATTGATGAAAATGCTGTGTC
AGAAGACCAGTTAATTAAGAGAACTATAGTTGGGATGATCAATGCAGTGTCTGTTGAA
GTGGGAGAGAAGAAATGTGGAAACCTGGCTTGTCTGCCAGATGAGAAGAATGTTCTTG
TTGTAGCCGTCATGCATAACTGTGATAAAAGGACATTACAAAACGATTTACAGGATTG
TAATAATTATAATAGTCAATCCCTTATGGATGCTTTTAGCTGTTCACTGGATAATGAA
AACAGACAAACTGATCAATTTAGTTTTAGTATAAATGAGTCCACTGAAAAAGATATGA
ATTGAGAGAAACAAATGGATCCATTGAATAGACCGAAAACAGAGGGGAGATCTGTAA
CCATCTGTCTCTACTTTCATCTGATAGTCTAGCCAGTGTCTGTTCCCCTTCACAATTA
AAGGATGACGGAAGTATAGGTAGAGACCCCTCCATGTCTGCGATTACAAGTTTAACGG
TTGATTGAGTAATCTCATCCCAGGGAACAGATGGATGTCTGCTGTTAAAAAGCAAGA
GAACTATATACCAGATGAGGACCTCACTGGCAAAATCAGCTCTCCTAGGACAGATCTA
GGGAGTCCAAATTCCTTTTCCACATGAGTGAGGGGATTTTGATGAAAAAGAGCCAG
CAGAGGAGAGCACCCTGAAGAATCCCTCCGGTCTGGTTTACCTTTGCTTCTCAAACC
AGACATGCCTAATGGGTCTGGAAGGAATAATGACTGTGAACGGTGTTCAGATTGCCTT
GTGCCTAATGAAGTTAGGGCTGATGAAAATGAAGGTTATGAACATGAAGAACTCTTG
GCACTACAGAATTCCTTAATATGACAGAGCATTCTCTGAATCTCAGGACATGACTAA
TTGGAAGTTGACTAACTAAATGAGATGAATGATAGCCAAGTAAACGAAGAAAAGGAA
AAGTTTCTACAGATTAGTCAGCCTGAGGACACTAATGGTGATAGTGGAGGACAGTGTG
TTGGATTGGCAGATGCAGGTCTAGATTTAAAAGGAACTTGCATTAGTGAAAGTGAAGA
ATGTGATTTCTCCACTGTTATAGACACACAGCAGCAAATTATCTATCTAATGGTTGT
GATTCCTATGGAATGCAAGACCCAGGTGTTTCTTTTGTTCCAAAGACTTTACCTCCA
AAGAAGATTCAGTAACAGAAGAAAAAGAAATAGAGGAAAGCAAGTCAGAATGCTACTC
AAATATTTATGAACAGAGAGGAAATGAGGCCACAGAAGGGAGTGGACTACTTTTAAAC
AGCACTGGTGACCTAATGAAGAAAAATTATTTACATAATTTCTGTAGTCAAGTTCCAT
CAGTGCTTGGGCAATCTTCCCCCAAGGTAGTAGCAAGCCTGCCATCTATCAGTGTTC
TTTTGGTGGTGCAAGACCCAAGCAACCTTCTAATCTTAAACTTCAAATTCCAAAGCCA
TTATCAGACCATTTACAAAATGACTTTCCTGCAACAGTGGAAATAATACTAAAAATA
AAAATGATATTCTTGGGAAAGCAAAATTAGGGGAAAACCTCAGCAACCAATGTATGCAG
TCCATCTTTGGGAAACATCTCTAATGTCTGATACAAATGGGGAAACATTTAGAAAGTTAT
GAGGCTGAGATCTCCACTAGACCATGCTTGTGATTAGCTCCAGATAGCCCAGATAATG
ATCTCAGAGCTGGTCAGTTTGGAAATTTCTGCCAGAAAGCCATTACCACGCTGGGTGA
GGTGGCTCCAGTATGGGTACCGGATTCTCAGGCTCCAAATTGCATGAAATGTGAAGCC
AGGTTTACATTACCAAAGGAGGCATCACTGCAGAGCATGTGGGAAGGTTTTCTGTG
CTTCCTGCTGTAGCCTGAAATGTAACTGTTATACATGGACAGAAAGGAAGCTAGAGT
GTGTGTAATCTGCCATTCAAGTGTGAATGCTCAAGCCTGGGAGAACATGATGAGT
GCCTCAAGCCAGAGCCCTAACCTTAACAATCCTGCTGAATACTGTTCTACTATCCCTC
CCTTGACGCAAGCTCAGGCCTCAGGAGCTCTGAGCTCTCCACCTCCCACTGTGATGGT
ACCTGTGGGAGTTTTTAAAGCACCTTGGAGCAGAAGTGGCTCAGCCCAGAGAGCAGAGG
CGAGTTTGGTTTGTGATGGGATCTTGCCCAATGGAGAAGTTGCTGATGCAGCCAAAT
TAACAATGAATGGAACCTTCTCTGAGGAACCTGGCTGTGTACACGACCCAGTCAA
GCCAGTAACCTACCAGTCTCTACCAGCAGAGACGGATATTGTCTATTCTCTGGGAGT
ATAACTCAGGTTGGAAGTCTGTTGGAAGTGCAATGAATCTTATTCTCTGAAGATGGCC
TTCTCTCCATTCTCATCTCCACTGGTGTAAAAGGAGACTATGCTGTGGGAAGAGAAACC
ATCACAGATTTCAAGTAATGCAGCAGTTGGAGGATGGTGGCCCTGACCCACTTGTATTT
GTTTTAAATGCAAATTTGTTGTCAATGGTTAAATTTGTAATTTATGTGAACAGGAAGT
GCTGGTGTTCACAACCAAGGGAATGCATGCAGTGGGTGAGTCTGAGATAGTCATTCT
TCTACATTGTTTACCGGATGAAAAGTGTGTTGCCAAAGGATATCTTTAATCACTTTGTG
CAGCTTTATCGGGATGCTCTGGCAGGGAATGTGGTGAGCAACTTGGGACATTCCTTCT
TCAGTCAAAGTTTCTTGGCAGTAAGAACATGGTGGATTCTTATATGTGACATCTAC

TABLE 1 - hSARA1 Continued

CTACCAGTCACTGCAAGACCTAGTACTCCCAACCCACCTTACTTGTGTTGGGATTCTT
ATCCAGAAATGGGAAACTCCTTGGGGCTAAAGTATTTCTATCCGTCTGATGTTGAGAC
TTGGAGCTGAATATCGACTTTATCCATGCCCCTATTTCAGTGTCAGATTTCCGGAAGCC
ATTGTTTGGAGAGACGGGGCATAACCATCATGAATCTTCTTGACAGACTTCAGAAATTAC
CAGTATACCTTGCCAGTAGTTCAAGGTTTGGTGGTTGATATGGAAGTTCCGAAAACCTA
GCATCAAAATTCCCAGCAACAGATACAATGAGATGATGAAAGCCATGAACAAGTCCAA
TGAGCATGTCCTGGCAGGAGGTGCCTGCTTCAATGAAAAGGCAGACTCTCATCTTG
TGTGTACAGAATGATGATGGAACTATCAGACCCAGGCTATCAGTATTCACAATCAGC
CCAGAAAAGTGACTGGTGCCAGTTTCTTTGTGTTTCAGTGGCGCTCTGAAATCCTCTTC
TGGATACCTTGCCAAAGTCCAGTATTGTGGAAGATGGTGTATGGTCCAGATTACTGCA
GAGAACATGGATTCTTTGAGGCGAGGCACTGCGAGAGATGAAGGACTTCACCATCACCT
GTGGGAAGGCGGACGCGGAGGAACCCAGGAGCACATCCACATCCAGTGGGTGGATGA
TGACAAGAACGTTAGCAAGGGTGTCTGTAAGTCCTATAGATGGGAAGTCCATGGAGACT
ATAACAAATGTGAAGATATTCCATGGATCAGAATATAAAGCAAATGGAAAAGTAATCA
GATGGACAGAGGTGTTTTCTAGAAAACGATGACCAGCACAAATTGCCTCAGTGATCC
TGCAGATCACAGTAGATTGACTGAGCATGTTGCCAAAGCTTTTTGCCTTGCTCTCTGT
CCTCACCTGAACTTCTGAAGGAAGATGGAATGACCAAACCTGGGACTACGTGTGACAC
TTGACTCAGATCAGGTTGGCTATCAAGCAGGGAGCAATGGCCAGCCCCCTTCCCTCGCA
GTACATGAATGATCTGGATAGCGCCTTGGTGCCGGTGATCCATGGAGGGGCTGCCAG
CTTAGTGAGGGCCCCGTTGTCATGGAACCTCATCTTTTATATTCTGGAAAACATCGTAT
AAACAGAGAAGACTTCATTTTTTTCTGTTTCAGACTTGTTGCAACAGCAGTCATACCCA
AATCATTTGCACTTTAAAACTGGAAGATTAAGCTTTTGTTAACTATTAATGGGGTG
GGGAATAGGGTGGGAGTGGGGGTTTGGGAGACGGGTGGGAAAGGGTGGTTGGGGGGAC
CGATGTTCCATAATTCTAAGTCTTCTATGCATTGTCCACCAAGAAGATCTGGGCAGCT
TCTGTTCTGCACAACAGTTATGCTATCCTTGACAGCTAATCCCCTTCTGTTACTGTTT
AGACAAGAATTCCGCTCCTCTCTCAAGATTTACTTATGGTCATGTGCTCAGAAATGCT
CAAATGGGTACAACCATCACCAAGGGTGGGATGGGAGGGCAGAGGGGAAATAAAATAT
AAAGCATCAAAAAAAAAAAAAAAAAA

TABLE 2 - hSARA1 - Sequence ID NO:2

MWIDENAVAEDQLIKRNYSWDDQCSAVEVGEKKCGNLACLPEDEKNVLVVAVMHNC DKR
TLQNDLQDCNNYNSQSLMDAFSCSLDNENRQTDQFSFSINESTEKDMNSEKQMDPLNR
PKTEGRSVNHLCP TSSDSLAVCSPSQLKDDGSGRDPMSAITS LTVD SVISSQGT D
GCPAVKKQENYIPDEDLTGKISSPRIDL GSPNSFSH MSEGILMKKEPAEESTTEESLR
SGLP LLLKPDMPNGSGRNND CERCS DCLVPNEVRADENEGYEHEETLGTTEFLNMTEH
FSESQDMTNWKLTKLNEMNDSQVNEEKEKFLOISQPEDTNGDSSGGQCVGLADAGLDLK
GTCISESEECDFSTVIDTPAANYLSNGCDSYGMQDPGVSFVPKTLPSKEDSVTEEKEI
EESKSECYSNIYEORGNEATEGSGLLLNSTGDLMKKNYLHNFC SQVPSVLGQSSPKVV
ASLPSISVPFGGARPKQPSNLKLOIPKPLSDHLQNDFPANSGNNTKNKNDILGKAKLG
ENSATNVCSPSLGNISNVD TNGEHLESYEA EISTRPC LALAPDSPDNDLRAGQFGISA
RKPFTTLGEVAPVWVPDSQAPNCMKCEARFTFTKRRHHCRA CGKVF CASC CSLKCKLL
YMDRKEARVCVICHSVLMNAQAWENMMSASSQSPNPNNPAEYCSTIPLOQAQASGAL
SSPPPTVMVPVGV LKHPGA EVAQPREQRRVWFADGILPNGEVADA AKLT MNGTSSAGT
LAVSHDPVKPVTTSP LPAETD ICLFSGSITQVGS PVGSAMNLI PEDGLPPILISTGVK
GDYAVEEKPSQISVMQOLEDGGPDPLV FVLNANLLSMVKIVNYVNRKCWCFTTKGMHA
VGQSEIVILLQCLPDEKCLPKDIFNHFVQLYRDALAGNVVSNLGH SFFS QSFLGSKEH
GGFLYVTSTYQSLQDLVLPTPPYLF GILIQKWETPWAKVFP IRLMLRLGA EYRLYPCP
LFSVRFRKPLFGETGHTIMNLLADFRNYQYTLPVVQGLVVDMEVRKTSIKIPSNRYNE
MMKAMNKSNEHVL AGGACFNEKADSHLVCVQND DGN YQTQAISIHNQPRKVTGASFFV
FSGALKSSSGYLAKSSIVEDGVMVQITAENMDSLROALREMKDFTITCGKADAE EPOE
HIHIQWVDDDKNVSKGVVSPIDGKSMETITNVKIFHGSEYKANGKVIRWTEVFFLEND
DQHNCLSDPADHSRLTEHVAKAFCLALCTQLKLLKGDGMTKLGLRVTLDSDQVGYQAG
SNGQHLPSQYMNDFDSDLVKMIHGGACQLSEGPVVMELIFYILENIV

TABLE 3 - human SARA2 - Sequence ID NO:3

ACTCCCGGCCGGGGTAGCTCTTCACTCCTCAGCGCGACGTCGTGTCGAGTTCCCAAAA
AGCTCCCGCAGGGGCTGTAGGGAGGTGATCTCATCCATTAAACAGCTGTGTGTTGCCAGT
TCCCAAATCTTTATCTATCTCAGACTTCTCTCCTGCATTCCAGATTCTTATATTTCAGC
TGCCCTTTTGGATATCTCTCCAGGATGTTCTCAAGGCATACAAGAATTAAATTCTGAA
TAAGTCTGCAGGTAGGATGGACAGTTATTTTTAAAGCAGCTGTGAGTACTTGGACAAA
CTCCTTGATGATTTTTGAACAGAACCAGATGAACAAGATTATCTCGCAGATGTACAAA
ATGCATATGATTCTAACCCTGCTCAGTTTCTTCAGAGTTGGCTTCCTCACAGCGAAC
TTCATTGCTCCCAAAAGACCAAGAGTGCCTTAATAGTTGTGCCTCATCAGAAACAAGC
TATGGAACAAATGAGAGTTCCCTGAATGAAAAAACAACCTCAAGGGACTTACTTCTATAC
AAAATGAAAAAATGTAACAGGACTTGATCTTTCTTCTGTGGATGGTGGTACTTC
AGATGAAATCCAGCCGTTATATATATGGGACGATAGTAGTAAACCTATCTGTGATCTGATA
AGTGACATGGGTAACTTAGTTCATGCAACCAATAGTGAAGAAGATATTAAAAAATTAT
TGCCAGATGATTTTAAGTCTAATGCAGATTCTTGATTGGATTGGATTTATCTTCAGT
GTCAGATACTCCCTGTGTTTCTTCAACAGACCATGATAGTGATACTGTGAGAGAACA
CAGAATGATATCAGTTCTGAATTACAAAATAGAGAAATCGGAGGAATCAAAGAATTGG
GTATAAAAGTAGATACAACACTTTTCAGATTCTTATAATTACAGTGGAAACAGAAAATTT
AAAAGATAAAAAGATCTTTAATCAGTTAGAATCAATTGTTGATTTTAACATGTCTCT
GCTTTGACTCGACAAAGTTCCAAAATGTTTCATGCCAAAGACAAGCTACAACACAAGA
GCCAGCCATGTGGATTACTAAAAGATGTTGGCTTAGTAAAAGAGGAAGTAGATGTGGC
AGTCATAACTGCCGCAGAATGTTTAAAGAAGAGGGCAAGACAAGTGTCTTTGACCTGC
AGCCTTCCGAAAAATGAAGATTTATGCTTAAATGATTCAAATTCAGAGATGAAAAATT
TCAAATTACCTGACTTTTCTTTTCAGGAAGATAAGACTGTTATAAAACAATCTGCACA
AGAAGACTCAAAAAGTTTAGACCTTAAGGATAATGATGTAATCCAAGATTCCTCTTCA
GCTTTACATGTTTCCAGTAAAGATGTGCCGTCCTCATTGTCTGTCTTCTGCGTCTG
GGTCTATGTGTGGATCATTAAATTGAAAGTAAAGCACGGGGTGATTTTTTACCTCAGCA
TGAACATAAAGATAATATACAAGATGCAGTGACTATACATGAAGAAATACAGAACAGT
GTTGTTCTAGGTGGGGAACCATTCAAAGAGAATGATCTTTTGAAACAGGAAAAATGTA
AAAGCATACTCCTTCAGTCATTAATTGAAGGGATGGAAGACAGAAAGATAGATCCTGA
CCAGACAGTAATCAGAGCTGAGTCTTTGGATGGTGGTGACACCAGTTCTACAGTTGTA
GAATCTCAAGAGGGGCTTTCTGGCACTCATGTCCCAGAGTCTTCTGATTGTTGTGAAG
GTTTTATTAATACTTTTTCAAGCAATGATATGGATGGGCAAGACTTAGATTACTTTAA
TATTGATGAAGGCGCAAAAAGTGGCCCACTAATTAGTGATGCTGAACTTGATGCCTTT
CTGACAGAACAGTATCTTCAGACCACTAACATAAAGTCTTTTGAAGAAAATGTAAATG
ACTCTAAATCGCAAATGAATCAGATAGATATGAAAGGCTTAGATGATGGAAACATCAA
TAATATATATTTCAATGCAGAAGCAGGAGCTATTGGGGAAAGTCATGGTATTAATATA
ATTTGTGAAACAGTTGATAAACAAAATACAATAGAAAATGGCCTTTCTTTAGGAGAAA
AAAGCACTATTCCAGTTCAACAAGGGTTACCTACCAGTAAGTCTGAGATTACAAATCA
ATTATCAGTCTCTGATATTAACAGTCAATCTGTTGGAGGGGCCAGACCTAAGCAATTG
TTTAGCCTTCCATCAAGAACAAGGAGTTCAAAGGACCTGAATAAGCCAGATGTTCCAG
ATACAATAGAAAGTGAACCCAGCACAGCAGATACCGTTGTTCCAATCACTTGTGCTAT
AGATTCTACAGCTGATCCACAGGTTAGCTTCAACTCTAATTACATTGATATAGAAAGT
AATTCTGAAGGTGGATCTAGTTTCTGTAAGTGCAAATGAAGATTCTGTACCTGAAAACA
CTTGCAAAGAAGGCTTGGTTTTGGGCCAGAAACAGCCTACTTGGGTTCTGTATTGAGA
AGCTCCAAACTGTATGAACTGCCAAGTCAAATTTACTTTTACCAAACGGCGACACCAT
TGCCGAGCATGTGGGAAAGTATTTTGTGGTGTCTGTTGTAATAGGAAGTGTAACTGC
AATATCTAGAAAAGGAAGCAAGAGTATGTGTAGTCTGCTATGAAACTATTAGTAAAGC
TCAGGCTATTTGAAAGGATGATGAGTCCAAGTGGTTCTAATCTTAAGTCTAATCATTCT
GATGAATGTACTACTGTCCAGCCTCTCAGGAGAACCAACATCCAGTATACCTTTCAC
CAGCAACTTTGCCAGTCTCAGCACTTAAACAACCAGGTGTTGAAGGACTATGTTCCAA
AGAACAGAAGAGAGTATGGTTTTGCAGATGGTATATTGCCCAATGGTGAAGTTGCAGAT
ACAACAAAATTATCATCTGGAAGTAAAGATGTTCTGAAGACTTTAGTCTCTCTCAC
CTGATGTGCCTATGACAGTAAACACAGTGGATCATTCCCATTCTACTACAGTGGAAAA
GCCAAACAATGAGACAGGAGATATTACAAGAAATGAGATAATTCAGAGTCTTATTTCT
CAGGTTCCATCAGTGGAAAAATTGCTATGAACACAGGAAATGAGGGGTTACCTACTT
CTGGTTCAATTTACACTAGATGATGATGTTTTTGCAGAACTGAAGAACCATCTAGTCC

TABLE 3 - human SARA2 - Continued

TACTGGTGTCTTAGTTAACAGCAATTTACCTATTGCTAGTATTTTCAGATTATAGGTTA
CTGTGTGATATTAACAAGTATGTCTGCAATAAGATTAGTCTTCTACCTAATGATGAGG
ACAGTTTGGCCCCACTTCTGGTTGCATCTGGAGAAAAGGGATCAGTGCCTGTAGTAGA
AGAACATCCATCTCATGAGCAGATCATTGCTTCTTGAAGGTGAAGGCTTTCATCCT
GTTACATTTGTCTAAATGCTAATCTACTCGTGAATGTCAAATTCATATTTTATTCTT
CAGACAAATATTGGTACTTTTCAACCAATGGATTGCATGGCTTGGGACAGGCAGAAAT
TATTATTCTATTGTTATGTTTGCCAAATGAAGATACTATTCTAAGGACATCTTCAGA
CTATTTATCACCATATATAAGGATGCTCTAAAAGGAAAATACATAGAAAACCTTGGACA
ATATTACCTTTTACTGAGAGTTTTCTCAGTAGCAAGGATCACGGAGGATTCCTGTTTAT
TACACCTACTTTTTCAGAACTTGATGATCTCTCATTACCAAGTAATCCTTTTCTTTGT
GGAATTCCTTATCCAGAAGCTTGAGATTCCCTGGGCAAAGGTTTTTCTATGCGTTTAA
TGTTGAGATTGGGTGCAGAATATAAAGCATATCCTGCTCCTCTAACAAGCATCAGAGG
CCGAAAACCTCTTTTGGGAGAAATAGGACACACTATTATGAACCTTACTTGTGACCTT
CGAAATTACCAGTATACCTTGCATAATATAGATCAACTGTTGATTATATGGAATGG
GAAAAGCTGCATAAAAATACCACGGAAAAAGTACAGTGAATGAAGTACTAAA
TTCTTCCAATGAGCATGTCTATTAGCATTGGAGCAAGTTTCAGTACAGAAGCAGATTCT
CATCTAGTCTGTATACAGAATGATGGAATTTATGAAACACAGGCCAACAGTGCCACTG
GCCATCCTAGAAAAGTGACAGGTGCAAGTTTTGTGGTATTCAATGGAGCTCTAAAAAC
ATCTTCAGGATTTCTTGCTAAGTCCAGCATAGTTGAAGATGGCTTAATGGTACAAATA
ACTCCAGAGACCATGAATGGCTTGCGGCTAGCTTTACGAGAACAGAAAGACTTTAAAA
TTACATGTGGGAAAGTTGATGCAGTAGACCTGAGAGAATACGTGGATATCTGCTGGGT
AGATGCTGAAGAAAAAGGAAACAAAGGAGTTATCAGTTCAGTGGATGGAATATCATT
CAAGGATTTCCAAGTGAAAAAATAAACTGGAAGCAGATTTTGAAACCGATGAGAAGA
TTGTAAATGTACCGAGGTGTTCTACTTTCTAAAGGACCAGGATTTATCTATTTTATC
AACTTCTTATCAGTTTGCAAAAGAAATAGCCATGGCTTGTAGTGTGCGCTGTGCCCT
CACCTGAAAACCTCTAAAAAGTAATGGGATGAATAAAATTGGACTCAGAGTTTCCATTG
ACACTGATATGGTTGAATTTCCAGGCAGGATCTGAAGGCCAACTTCTGCCTCAGCATT
TCTAAATGATCTTGATAGTGCTCTGATACCTGTGATCCATGGTGGGACCTCCAACCTCT
AGTTTACCATTAGAAATAGAATTAGTGTTTTTTATTATAGAATCTTTTTTAGTGAA
AGAATGTGCCATATTACATATTGCAACCTAATTTGTTAAACTAACTCCAGCACTAAA
GCTGAAATGCCACAAACACTAAAAGTATAAATATGTCTGATTTTTGAAACACATAAGC
TTTGCTCTTTAGGCAGGAATGATCTTTTCAAATCATTAGCACAAATATTAAATATCTA
AAAATTTAAGAGATCCATACTTTCTGTAGCTTTACAATTAATTTAAGTACTAAAAAGA
CAAGGATTTCTTTTAAGAAATTTATAGCATTACTGTGTTATTTAAATGCTAAGCCAA
AGTATCTGCACTTAGGTATACCTCTTTATGCCAATAATGATTTTAAATGAAGGCTCTTT
TCAGATGTAACTTATGAAGGAAATATCTGCTTTGTGTATATGCCAGTTAGAATACTG
GTTTCTAAAGTCTGTCAAATTGTATTTTCAAGTGGCACAACCAAGTTTTGAGGTCTTA
GACTTATAAATTTTGAATAAACTGATAACTTATTTGTATAAATTGGAGTGGAGACCT
ACCTCCATAATTAGATAAACTCTTTTGGATTATAATCAGAATTTTGCCCTTTTTCTT
CTCAAATTATTACATATGTATGTATTATATATCCACATATATAGTTTTCCCTGATTAA
ATGGATATTAAATAAATTGCGGGTGCTTCAGGACTTTTTGCTTCTATATTTAAGTATA
TTGTTTTTATAGCAAGAACATATTCTGAATGTTTTATAAATCTTTAATAATTTATATG
TAGGTAATATTTTGTATCACAATGCATTATTTTTTTTCTCCTTCTTCCAACTA
TACCACTGTATTTACCACTTCTAAGAGTGACTGACGACGGGCCAGATGACCCTTGAAG
TAGTCATTATGTAGCAATAAATGAAGCCTGAAACAGGTTTTTTTTTACTTCCACTTTAAT
CCTTAGAAATTTCTTGGCAACTTCGCATATTTTCATTGACACTGGTGTATAAGTATAA
ATTAAATGAACATAATTACTTTTGCATATTTTAAATTTCTTTATATGGTAGTTATTTT
TATAACAGGATATTTACATAAGTTAAATCTTATGTATTTGAAATTGTTACAGAGCTTT
CCTCTTTACTTCAAACAGCAAAAAGTGGGGGCATATTGTAGTCTGTCAATTTAAGT
TATGTAAAAAATTTAATCATTATTTTGTATGCTTTTAAACATTCTCATGTGAATATATG
TTTTTGTATCAAAAACACTCATATATTTCAAGAAAAAGAAATTATGTTAAATAGCCCT
GTTTTAAGAAAAATATTTATGAAGCATCTCAACTTGAAGATCAAGTCAAAGTTATAAC
TCAGGATCTGAGGTCTCAAGCTAGGAGAGACTGAGAATTTTAAATCAGTTTGGGCATAT
AGTTTGGACTGAATCACAATCTGTAGTACTTAGCCAAAGACAATTTGGAGGAGAAATATC
AGCCTTCTGGAAGTAGCTACTTCTGAAACATGTAAAGTCTGCGAGATATTCATAAAA

TABLE 3 - human SARA2 Continued

ATGGCAACCTGTTATAATTTGTGAAATTTATTGAAATGGTGTAGATGAAAACAATTG
CATATCAAACCCAATTTATGTTTTCTAAATATAGTGTATGTATTCTGCCATGTAAGTA
ATTGAACAGTCTTAAAATAACCAAATGGTAGAGGGCTGTTCCATGATGGGACAGCTTT
GGATTGTTTTCATAAAATCTCTACATTCAATAAAAATTGGAATTATGTGCCTGAAGT
TTGGAGGCACATTTTGAAGT

TABLE 5 - XSARA1 - Sequence ID NO:5

CTGTAAGTTTTGACTATGTAGGAAAGCATTCTCTGTTATCTATGAAGTATGTTTTAGAGT
CAGACCAATAACTAAACGGTTTTCTTTTTTTTTGTTTATTTCCCTCAGATGAGACTGT
CTCTCCAAAGCTATTAGATGCTAAGTGGAATCAAATCTTAGAACCGCATTACATAAA
GTCGCTGATAACTCCGCCCTTGACAATGTCTGTAAATCAATCATTGCTATTGAAGCTC
ATCTCAAAGTCAGGTCACCCGGCTTGTGAGCCCTTGTGAGGTCCACATATGTGAATGG
AGAAGTAGGTATTGTGGCACCTGAAATGCCCAAATGGTGTATAGGAGACACCATTATG
GCAGAGGATTCACTTTTTTAACAACACTGGTCCCTCTGAAATTGTATGCAACCCATCTA
CTGTGGAGAGTCAAAGTTTACAAGCTTTAGATGATCAATCAGTGAATATTCACAATGA
AAAAAGTGTCTGCTCGCTGATGGCTTTTACCATGCAGTAGCCCCAAAAGTATTATA
AAGTTGACTGCTTGACCATGGATAACGAAATGCCCTTTCACAGTCAAATGAGTGTG
ATGACAATGACAAAGAACTGTAACAATTTTCAGTCCCTTCCAACAATCATACAGGATAC
TAGTAACGTAAGCACAGACCCAGCTATCAATAAACCTGGCACTAAAGAACCCCATAGA
GCATTAAAGGAAACCACATCAGTTATTCTGCCTGAAATAAAGCCTTACTCCACATGTG
CTGCCCTTTTCGTTTGAAAATAACAATAAGGTTCCAGTTATCAATTAAATAATACAGA
TCTACTCAGCGTTTACCAGTGGTTGAAGCATGTAGTGAGCAGCAGCAAAAACATACA
TCTTCTTTCATGAAGAAAACTTTTTGAAGGTGTTTCTGCAACGGAGTCTTTGCGAG
CCACTGCTGCGGAACTGTACTGGATAATGAGGCTCTCCGTAGTGCTGAATTCTTTGA
CATTGTTGTAAAGAACTTTTCTGACTCTTGTGTGATTAATGGCGACTTGACTAAAAGT
TGTGGCCTCTCTCAAGAAAGCAATGAAAAGTTTTGTGCAAGTAAAGAGTTGAAGGAG
GGGTAGATGCTAATGTCTTGTGTTGAAAATGCATGTGTAGCTTATAAAGAAGCAATAGA
TTTGCTGAAAGAAAATGGAACATAATGCACCAATGTCTCTGTACAAATGGGTGTGATTCC
TATGGAATGAAAAACCCAGCCGTAGCTCAAACCCAAAGAATTTACCTTCAAAGAAG
ATTCTGTGACAGAAGAAAAGAAATTGAAGAAAGCAAGTCAGAATACTATACTGGTGT
TTATGAACAACAAAGAGAAGATGATGTTACAGAGAGAGGTGGACTTCTGTAAATGCT
AAGGCTGACCAAATGAAGAACAATTTGCATAGTCTTTGTAATCAGGTTCCATCCATGC
ATGGGCAAACATCACCAAAAAGGGCAAGATTGTGCAATCTCTCAGTGTTCATACGG
TGGAGCACGCACTAAGCAGCCAACTCATCTCAAACCTCCATATTCCAAAGCCATTGTCT
GAAATGTTGCAGAGCGATCTCATTCTCTCAAATGCTGGCTGCAGCTCTAAATACAAA
ATGACATGTTAAACAAATCAAATCAGGGGGATAACCTGATTTCAGAAATCACTCGCTGA
GGATTCTGCAGTGCAGCCCTGTTTACTGATGCTAATGGTGATTTCCTGGAGAATAC
AGGGGACCTGGCAGCTTGTGCCCTTGCAGTGTCTCCAGACAGCCCAGACAACGATCTGC
TTGCCGGGCAGTTTGGGGTACCCATCTCTAAGCCATTTACTACTCTAGGGGAAGTGGC
TCCAGTCTGGGTGCCAGATTCCCAAGCACCAACTGCATGAAGTGCAGGGCCAGATTT
ACATTTACCAAAGGAGGCATCACTGCCGAGCTTGTGGAAAGGTGTTCTGTGCTGCTT
GTTGCAGTCTAAAATGCAAACCTACAGTACATGGATAAAAAGGAGGCTCGTGTGTGTGT
TATTTGTCTTCTGTGCTTATGAATGCTCAAGCATGGGAGAACATGTTAAGTGCATCG
GTCCAAAGCCCAAATCCAAATAATCCTGCTGAATACTGCTCAACTATCCCTCCGATGC
AGCAGGCAACAAGCTTCAGGAGCACTGAGTTCCTCCACCTCCCACTGTCTGGTGGCAGT
GGGTGTGTTAAACATCCAGGAACCTGAAGGTCACAGTCAAAGGAACAGCGCCGTGTT
TGGTTTGTGATGGAATATTACCCAACGGAGAGACTGCTGACTCAGATAATGCAAACG
TAACTACAGTGGCTGGGACACTTACTGTGTACATACCAACAATTCACATCTTCAGA
GTCTGAGAACACCTCTGGATTCTGTGGAAGTATAACTCAGGTTGGCAGTGCAATGAAC
CTTATTCCAGAAGATGGGCTTCTCTCTATACTAATCTCTACTGGAGTAAAAGGAGATT
ACGCAGTTGAGGAACGCCCTTCCAGATGTCTGTGATGCAGCAACTAGAGGAAGGAGG
ACCAGATCCTTTGGTTTTTGTCTAAATGCAAATCTTTTGGCCATGGTTAAGATCGTG
AACTATGTTAACAGGAAATGCTGGTGCTTTACTACAAAGGGAATGCATGCAGTGGGCC
AGGCTGAGATCGTAATCCTGTTGCAGTGCCTGATGAGAAGTGCTGCTCCGAGGGA
CCTGTTTAGCCATTTTGTGAGCTGTATCAGGAGGCAATTGCAGGTAATGTAGTGGGG
AACCTGGGGCATTCCTTCTCAGCCAGAGTTTCTTGGGTAGTAAGGATCATGGTGGAT
TTCTTTATGTTGCACCAACCTACCAGTCCCTCCAGGACCTGGTTCTTCTGAGAGCC
GTACTTGTGTTGGAATCCTTATTCAAAGTGGGAGACTCCATGGGCCAAAGTGTTCCTC
ATTGGGCTTATGCTGCGTTTAGGTGCAGAATACAGATTGTACCCATGTCCACTCTTCA
GTGTTTCGATACAGAAAACCTCTGTTTGGGGAAACCGGACACACCATCATTAATGTTCT
AGCCGATTTCAAGAACTATCAGTATACTCTGCCAGTGGTGCAGGGCTTGGTGGTGGAT
ATGGAAGTCAGAAAACTAGCATTAATCCCAAGCAATAGATACAATGAGATGATGA
AAGCAATGAACAAATCCAAATGAGCATGTGTTGGCCATAGGAGCATGCTTCAACCAGAT

TABLE 5 - XSARA1 Continued

GGCAGACTCTCACCTTGTGTGTGTGCAAAACGATGATGGCAATTACCAGACCCAGGCA
ATTAGTATCCACAAACAACCACGTAAAGTGACCGGGGCCAGCTTCTTTGTCTTCAGTG
GTGCACTAAAGTCTTCTTCCGGATACCTGGCCAAATCCAGCATAGTAGAAGATGGGGT
AATGGTTTCAGATCACCGCAGAGAGCATGGATGCCCTCAGACAGTCCCTTCGGGAGATG
AAGGATTTCCACCATTACATGTGGAAGCTGATGCAGAGGAGTCACAGGAACATGTCT
ATGTCCAGTGGGTGGAGGATGACAAGAACTTTAACAAGGAGTTTTTAGTCCAATCGA
TGGCAAATCAATGGAGTCTGTGACCAGCGTCAAGATTTTTCATGGCTCAGAATACAAA
GCTAGTGGAAAAATAATTGCTGGATAGAGGTCTTCTTTCTGGACAATGAGGAGCAAC
AGAGTGGCCTGAGTGACCTGCTGATCACAGCCGACTCACTGAAAATGTGGCCAAAGC
ATTCTGTTTAGCGCTTTGCCCACACCTCAAGCTACTGAAGGAAGATGGAATGACCAGG
TTAGGTCTGCGGGTGTCACTGGACTCAGACCAGGTTGGATACCAAGCTGGGAGCAATG
GGCAACTCCTGCCTGCCCGATACCAATGATTTGGATGGTGCTTTGGTACCAGTGAT
ACACGGGGGCACATGCCAGTTAAGTGAAGGGCCTGTCAGTATGGAGCTGATATTTTAT
ATCCTTGAGAACATCTCCTAGGAAAGACACATGTGTCTCCTCACAAACTGCCATCGCC
CAAACCATTTGCACTTTAACCGCAAAAGATTCATTTTTCTTTTCTTTTGCTAACACTA
GTATTAGGTCAGGGTGCGAGAGGCAGACACCTGAACTCTTAAACCTTCTATGCATTTT
CACAGTAAGGATCAAGCTGCAGCTGGGAATTTCTGTACTAATCCAATGTGGGACGT
TAGAAGTGATCGGTGGCACTGACTATCTAGCTGTTCAACCTTCTCTGGCTCCTCTAAG
GACTCTAGTGCCAGGGGGTGAGACATTCAAGTTTAAAACGAAAACCTCTAAATACAATC
AGGAATCTCACTCTGACCTCATTTAAATCATCACTGCGACTTTTTTTCTGCTCGCAT
TCTTTATTTTGCATCTTACTCAAGTTTACATTGTCAAGACCAGCCTAAGCCTTCAGTC
CTTTCTCAATTAACTACTCGTGCATGGCAAGGAGACTTTCGTTGCACAGCCTGAAAT
ATACCAATCACTTCCCAAACCAAGCATGAATCCAACGTTTTCTGACTGGTTGGCT
CTGCTGTGAAAGGGACAGCAATATTATTTTTCTACAGTTGACAAAACCTTTGTCTATG
TCTGTGTCTCTCATGGGGGATTGTTGCCTGATGGGCAGCCTCCGGAGAGAAGAATTC
CACCCGTGTGTAATATACAGTCTAAGTGTATGGTCTGCTATGTAACACCTGTTGCGCA
GTGCAAATGCACTGACTCTCTGGAAGGCTATAGAGTTTTTAAAACGGTTAGTCTTTTA
AAAAAAA

TABLE 6 - XSARA1 - Sequence ID NO:6

MPKMVIGDTIMAEDSLFNNTGTPSEIVCNPSTVESQSLOALDDQSVNIHNEKSVLLADG
FSPCSSPKSIINFDCITMDNEMPLHSQMSVDDNDKETVTISVLPTIIQDTSNVSTDPA
INKPGTKEPHRALKETTSVILPEIKPYSTCAALSFENNKNKVPYQLNNTDLLSVSPVV
EACSEQQQKHTSSLHEEKLFEQVSATESFAATAAETVLDNEALRSAEFFDIVVKNFSD
SCVINGDLTKSCGLSQESNEKFCASKEFEGGVDANVLLNACVAYKEAIDLPEENGNTN
APMSLYNGCDSYGMKNPAVAONPKNLPSKEDSVTEEKEIEESKSEYYTGVEEQOREDD
VTERGGLLLNAKADQMKNNLHSLCNQVPSMHGQTSPPKKGKIVQSLSVPYGGARTKQPT
HLKLHIPKPLSEMLQSDLIPPNAGCSSKYKNDMLNKSNOGDNLISESLREDSAVRSPV
TDANGDFPGEYRGPGLCLAVSPDSPDNLLAGQFGVPISKPFITLGEVAPVWVPDSQ
APNCMKCEARFTFTKRRHHCRACGKVFCAACCSLKCKLOYMDKKEARVCVICHSVLMN
AQAWENMLSASVQSPNPNPAEYCSITPPMQQAQASGALSSPPPTVMVPVGVVLKHPGT
EGSQSKEQRRVWFADGILPNGETADSDNANVTTVAGTLTVSHTNNSTSSSENTSGFC
GSITQVGSAMNLIPEDGLPPILISTGVKGDYAVEERPSQMSVMQOLEEGGPDPLVFVL
NANLLAMVKIVNYVNRKCWCFTTKGMHAVGQAEIVILLQCLPDEKCLPRDLFSHFVEL
YQEAIAGNVVGNLGHSFLSQSFLGSKDHGGFLYVAPTYQSLQDLVLPAPYPLFGILIQ
KWETPWAKVFPIRLMLRLGAERYRLPCPLFSVRYRKPLFGETGHTIINVLADFRNYQY
TLPVVQGLVVDMEVRKTSIKIPSNRYNEMMKAMNKSNEHVLAIGACFNQOMADSHLVCV
QNDDGNYQTOAISIHKQPRKVTGASFFVFSGALKSSSGYLAKSSIVEDGVMVQITAES
MDALRQSLREMKDFTITCGKADAEESQEHVYVQWVEDDKNFNKGVSFPIDGKSMESVT
SVKIFHGSEYKASGKIIRWIEVFFLDNEEQQSGLSDPADHSRLTENVAKAFCLALCPH
LKLLKEDGMTRLGLRVSLDSDQVGYQAGSNGQLLPARYTNDLDGALVPVIHGGTCQLS
EGPVSMELIFYILENIS*

TABLE 7 - XSARA2 - Sequence ID NO:7

AGTTTTATTTTCAGAAGACGTTGCATCTTTATTTTAAACATTAAAGTTTCACATATGTAG
TAAACATTACTGTTGTATATACAGTATGTTGTAGACATATAACGTAAGTGTGCTT
TGTGCTTTCTTTCTCCTCAGATGAACTGTCTTTCCAAAGCTGTTAGATGCTAAGTG
GAATCAATTCTTAGAACCACATTTCGCATAAAGTCACTGATAAACAGCTCTTGACAAT
GTCTGTAAATCAATCATTGCTATTGAAGCTCATCTCAAAGTCAGGTCACCCAGCTTGA
CAGCCCTTGCAAGGTCCACATATGTGAATGGAGAAGTAGGTATTGTGACTCCTGAAAT
GCCTAAAATGGTGATAGGAGACCCGATATGGCAGAGGATTCACTTTTTAACACTGGT
CCCTCTGAAATTGTATGCAACTCTATTGTGGAGAGTCAAAGTTTAGAAGTTTTAGATG
ATGTACCAGTGAGTATTAACAATGAAAAAGTGTCTTCTTGATGATGGATTCTCTCC
GTACAGTAGCCCCAAAAGTGTCTAAACTCTGCTTGCTTGACCATGAATAACGGAAAG
CCCTCACACGGTCAAAAATTGTTAATGACCAAGATAAAGAAGCTGTAACAATTTTCAG
TCCTTCCAATGATCATAACAGGATACTACTAACGTAAGCACAGACCCAGCTTTCAATAA
ATCTGGCACTGAAGAAGCTTATAGTGCATTAAACAAACCACATCAGTTATTCTGCCT
GAAATAAAGCCTTATTCATACAGGCTGCCCTTTCATGTGAAAATATCAACAAGATAC
CCAGATGTCAATTAAATAATACAGATCTACTCAGCATTTCACCAAGTGGTTGAAGCATG
TAGTGAGAAGCAGCAAAATCATACAACTTCCTTGCAATGAAAAAACTTGCAGCTGTG
TCTGCAACTGCGTTCTTTCCAGTCACTGCTGCTGAACTGTACTAGGTAATGAAGCTC
TCCATAGTGCTGATTTTTTTGCATTGTTGTAAAGAACGTTTCTGACTCGTGTGTGTT
TAATGGTGACCTAACTAGAACTAATGGACTCTCACAAGAAAACAATGAAATGTTTTAT
GCAAGTAAAGAGTTGGAAGGAGGGGTAGATGCTAATATCTTATTGGAAGATGCATGCA
TAGCTTTATAAAGAAAGAATAGATTTGTCTGAAGAAAATGGAACCTAATGCACCAATGTA
TCTGTACAATGGGTGTGATTCTATGGAATGAAAAACCTGCTGTACGTCAAACCCCA
AAGAATTTACCATCAAAGAAGATTCTGTGACAGAAGAAAAGAAATTGAAGAAAGCA
AGTCAGAATACTATTCTGGTGTTTATGAACAACAGAAGGAAGATGACATAACTGAGAG
AGGTGGAGTCTTGTTAAATGCCAAGGTTGACCAATGAAGAACAGTTTGCATAGTCTT
TATAATCCGGTTCATCCATGCATGGGCAAACCTCACCAAAAAGGGCAAGATTGTGC
AATCCCTCAGTGTTCATATGGTGGAGCTCGCCCCAAGCAGCCAACTCATCTCAAACCT
CAATATTCACAGCCATTGTCTGAAATGTTACAGTGTGATCTCATTCCGCCAAATGCT
GGATGCAGCTCTAAAAACAATAATGACATGTTAAACAAATCAAATCGGGGGGATAACC
TGATTTTCAAGATCACTACGTGAGGAAGTGACAGCCCTGTTACTGATACAAATGGTGA
AGTCCCTCGAGAAAACAGGGGACCTGGCAGCCTGTGCCTTGCAAGTGTCTCCAGACAGC
CCTGACAATGATCTGCTTGCTGGACAGTTTGGGGTACCCATCTCTAAGCCATTACTA
CTCTAGGGGATGTGGCTCCAGTCTGGGTGCCAGATTCCCAAGCACCAAACCTGCATGAA
GTGCGAGGCCAGATTTACATTTACCAAAGGAGGCATCACTGCCGAGCTTGTGGAAAG
GTATGTAAAGAAATGTGGTGTTCATCAGGGCAACAGTAATCACGGCAAATTATTTCAT
AACAAAATGTGTTTCAAGCAGATTCAAGTTAAAGTAGACTTATAAGTTACACAGTAACAAT
TCATCTGCTCAGCCTCATTTTTGAAGTAGATAAAATATATTTTATTAGGAACTCTGGG
GAGATATAAGGGAAAGCTTGCCCTAAAAGTAGATGTTCTGTATATTATTGGTAGTCAA
AGATGATTTTCATGAAAAAGGTTATTTGTAAAAAGTACAAAATGGGTAGAGACTAGAC
AATAAAAAGTAAGGAGTAAAAAACTAGGTATGTAACTATATTTAAATAATTTTATGA
TTTTAATATTTTACTGCACATTTTCTACAGTGCAGTGATTTGTATAACCATGCAATTAT
CAAATGCTTAGTGCTTCCACACAAAGTGCTTTAATAAAAATTATTTTATAAATTATC
ATATTTTCTTTATATGTAGTCATCATCTTTTTTGTCTCATTTCTTGGAAATCGTTCTAC
TTATGTTCTACTGATATGTTTTTACCCGAGACCTATCTTGTCTCTAAAGTAATTGG
CTTGTCAACTGGCTGTAGGGGGATTTTCAGAGTTATAGCTTAGTACTGTTAATGAGCC
ATAGGTTGAAATAGTGCTCTAGATTTACATGTTGTACAACAGTTATTGCAATATGTGT
AGGGGGGGGG

TABLE 8 - XSARA2 - Sequence ID NO:8

MPKMVIGDITDMAEDSLFNTGTPSEIVCNSIVESQSLEVLDDVPVSINNEKSVLLDDGFS
PYSSPKSVLNSACLTMMNGKPSHGQKIVNDQDKEAVTISVLPMI IQDTTINVSTDPAFN
KSGTEEAYSALKQTTSVILPEIKPYSIOAALSCENINKIPRCQLNNTDLLSISPVEA
CSEKQQNHTTSLHEKKLAAVSATAFFPVTAETVLGNEALHSADFFDIVVKNVSDSCV
FNGDLTRTINGLSQENNEMFYASKELEGGVDANILLEDACIAYKERIDLSEENG TNAPM
YLYNGCDSYGMKNPAVRQNPKNLP SKEDSVTEEKEIEESKSEYYSGVYEQQKEDDITE
RGGVLLNAKVDOMKNSLHSLYNPVPSMHGQTS PKKGKIVQSLSVPYGGARPKQPTHK
LNIPQPLSEMLQCDLIPPNAGCSSKNKNDMLNKS NRGDNLISESLREEVHSPVTD TNG
EVPREN RGPGSLCLAVSPDSPDNDLLAGQFGVPISKPF T T L G D V A P V W V P D S Q A P N C M
KCEARFTFTKRRHHCRACGKVCKEMWCFIRATVITANYS

62

TABLE 9

NSARA	MAIDENVAEDCLIKRNNYSWDDGSAVENGERKCGNACLPDEKNVLLVAVVMMHC DKRTLONDLODNNYNSDGLMC	7
XSARA	MPKMYVGDITIAEDSLFNMTGPSEIYCHNPS TVESE...SLGALDDOS...VNIMNIEKSVLLADGFSPTSSP...KSIIN	70
NSARA	AFELSLDENROTDGFSFSINESTEKDMNEKONDP LMPKTEGOREVNMCPPTSSESILASVCSFSLKDDGSI	157
XSARA	FDCLITMDN...EMP LNEGMSVDONDK...ETVTISVLTPTIIGDTSNVSTIDPAINKIP...ETKEPHR	127
NSARA	ATISLTVDSVSISSGTDGSPAVKKEEYIPDEDLYGKISSPRITDLCSPNSFSEHMSSEGLMKKEPAEESTTEESRSGLP	236
XSARA	ALKETTSVILPEIKPYS TGALES FIENMKVPISYDNL...NITDLS...VSPVVEACSEIQOONNTSELNKEKLFEDVS	108
NSARA	LLKPDMPNGSGRNDCCERCSOCLVPNEVRADENEGYEHEETLCTTEFLNHTERFSESODMTNWKLTKLNEHNDOSVNEE	316
XSARA	ATES...FAATAATVLDNEALNSAEFFDIIVVKNFSOSCVIINGDLTKISCGLS...OES	250
NSARA	KERTLOISPEEDTNGDSGOCVGLADAGLDKGTCTSESECEPSTVIOTPAANYLSNGCOSTGMODGVSFVFKILPSR	306
XSARA	NEKPCASKFE...GG...VDANVILLEACVAYKEAIDLPENGTNAPMSLTNGCOSTGMKNPAVAIONPKNEP	318
NSARA	EDSVTEEKEIEESKEEYYSNIYEQFONEAREGSDLLNLSITGLMKNNYLNHNFESDVPFVILGSSPKVVA SLPISVFPFQ	475
XSARA	EDSVTEEKEIEESKEEYITGVYEQOREDOVTERGOLLNNAKADOMKNNLHSLCINOVPMSHGOOTSPPK GKIVDLSVPG	308
NSARA	GAMPKOPSNLKLQJPKPLEDHLCNDFFANSONNITKKNDIAGKAKLENSATNVCSPSLGNI SNVDTNGEHLSEAE	553
XSARA	GANTKOP THLKLHJPKPLESEM LGSNLIIPNACCSISKYKNOMUNKSNODNLISSLRDESAVRSPTDANGDIFPGEYRGP	478
NSARA	ISTRPCLALAPDSPONDLRAGOGFISARKPETTLGEVAPVWVWDSOAPNCKMCEARFTFKRRHMCACQKVFCAACCSL	633
XSARA	GS...LCLAVSPDSPONDRLAGOGFVPISKPTTLGEVAPVWVWDSOAPNCKMCEARFTFKRRHMCACQKVFCAACCSL	556
NSARA	KCKLTYMDKKEARVCVICHSVLMNAQAWENMHASGDSPPNPNPAEYCYSTIPPLQQAQAGSGLSSPPPVMVVPVGVKHP	713
XSARA	KCKLTYMDKKEARVCVICHSVLMNAQAWENMLGASVDSPPNPNPAEYCYSTIPPLQQAQAGSGLSSPPPVMVVPVGVKHP	636
NSARA	GAEVAPREGRRVWFADGLLPNGEYVADAIAKLTNIGTSSAGTLAYRPPVKPVITTEPLPAETDIEFGSGITOVGSPYGBA	703
XSARA	DTEGSSGKEORRVWFADGILPNGEYVADSID...MANVITVYAGTLVSNTHNS TSSE...ENTSGFCGSTTOVG...EA	705
NSARA	MNLIPEDGLPPIILISTGVKQDYAVEEKPSQISVMQGLEDDQDPDLVFLVLANHLLSMYKLVNYVNRKWCWCFITTKMHAVGG	873
XSARA	MNLIPEDGLPPIILISTGVKQDYAVEERPSONEVMQGLEDDQDPDLVFLVLANHLLAMVKLVNYVNRKWCWCFITTKMHAVGG	785
NSARA	SEIVILLQCLPDEKCLPKDIFNHFVOLYRDALAGNVVSNLQHSFFESQFLOSKEHGGFLYVTSITYOSLODLVLPAPYLF	853
XSARA	AEIVILLQCLPDEKCLPKDIFSHFVELYOEIIMONVVGNLQHSFLSQSFLGSKDHGGFLYVAPITYOSLODLVLPAPYLF	845
NSARA	QILHOKWETPWAKVFPILRLMLRLGAERYLYPCPLFSVRFRKPLFGQETQHTLMNLLADFRNYQYTLPPVVOGLVVDMEVART	1033
XSARA	QILHOKWETPWAKVFPILRLMLRLGAERYLYPCPLFSVRFRKPLFGQETQHT4INVLADFRNYQYTLPPVVOGLVVDMEVART	845
NSARA	SIKIPENRYNEMMKAMNKSNEHVLADGACFNQADSHLVGVONDDGNYOTOAISIHNDPRKVTGASFFVFGALKSSSEGY	1113
XSARA	SIKIPENRYNEMMKAMNKSNEHVLADGACFNQADSHLVGVONDDGNYOTOAISIHNDPRKVTGASFFVFGALKSSSEGY	1025
NSARA	LAKSEIVEDGVMOITAEINMSLRQALREMKDFTITCOKADAEPDENHIIOWVODDKMVSQGVVSPIDGKSMETITMVR	1183
XSARA	LAKSEIVEDGVMOITAEINMSALROS LREMKDFTITCOKADAESDENHIIOWVEDDKMIFNKGVSFSPIDGKSMESVTSK	1105
NSARA	IFHQSEYKANKVHRWTEVFFLENDODDHNCELDPAHMSRLTENVAKAFCLALCPHLKLLKEDGMTRLGLRVSLDSQVGY	1273
XSARA	IFHQSEYKASOKISRWTEVFFLDNEEQDSGLEDPAHMSRLTENVAKAFCLALCPHLKLLKEDGMTRLGLRVSLDSQVGY	1185
NSARA	DAGENGOLLPSONYHOLDLSALVPKIIHQGACOLSEGPVIMELIFYLENIN	1323
XSARA	DAGENGOLLPARYTNDLGDALVPVIIHQGTOLSEGPVIMELIFYLENIN	1235

TABLE 10

NSARA	587	CEVAPVWVWDSOAPNCKMCEARFTFKRRHMCACQKVFCAACCSILKCKLDYMDKK	655
XSARA	510	LGEVAPVWVWDSOAPNCKMCEARFTFKRRHMCACQKVFCAACCSILKCKLDYMDKK	578
KIAA0305	737	LGOKOPTWVWDSOAPNCKMCEARFTFKRRHMCACQKVFCAACCSILKCKLDYMDKK	800
FGD1	720	LGRAPTPIREKERTDMHCOIEPFNSITKRRHMCACGHVPCGKCEFRALNKNNA	485
Hrs	153	ATERAPDWD...KEECPHCRVDFGMDTKHMCACGQIFCGKCSSKTB	219
Hrs-2	153	AAERAPDWD...AECHRCRVDFGMDTKHMCACGQIFCGKCSSKTB	219
EEA4	1341	TOALNAKAKEDNENONCMAKCKJF5VTYRRHMCACGQIFCAECSAKNAL	1408

CONSENSUS.....P-W.....C..C...F.....RKHORACG-VFCG-CG.....RVC..C...L

WE CLAIM:

1. An isolated polynucleotide comprising a nucleotide sequence encoding a SARA protein or a splice variant thereof.
- 5 2. The isolated polynucleotide of claim 1, wherein the SARA protein is a mammalian SARA protein.
3. The isolated polynucleotide of claim 1, wherein the SARA protein is a
10 non-mammalian SARA protein.
4. The isolated polynucleotide of claim 2, wherein the SARA protein is a human SARA protein.
- 15 5. The isolated polynucleotide of claim 3, wherein the SARA protein is a Xenopus SARA protein.
6. The isolated polynucleotide of claim 1, wherein the nucleotide sequence is selected from the group consisting of
 - 20 (a) a nucleotide sequence encoding the amino acid sequence of Sequence ID NO:2;
 - (b) a nucleotide sequence encoding the amino acid sequence of Sequence ID NO:4;
 - (c) a nucleotide sequence encoding the amino acid sequence of
25 Sequence ID NO:6;
 - (d) a nucleotide sequence encoding the amino acid sequence of Sequence ID NO:8; and
 - (e) a nucleotide sequence encoding a SARA protein and capable of hybridising to a sequence complementary to the nucleotide sequence of
30 any of (a) to (d) under stringent hybridisation conditions.

7. The isolated polynucleotide of claim 4 comprising the nucleotide sequence of Sequence ID NO:1 or a degeneracy equivalent thereof.
8. The isolated polynucleotide of claim 4 comprising the nucleotide sequence of Sequence ID NO:3 or a degeneracy equivalent thereof.
9. The isolated polynucleotide of claim 3 comprising the nucleotide sequence of Sequence ID NO:5 or a degeneracy equivalent thereof.
10. The isolated polynucleotide of claim 3 comprising the nucleotide sequence of Sequence ID NO:7 or a degeneracy equivalent thereof.
11. An isolated polynucleotide comprising a nucleotide sequence of at least 10 up to the total number of consecutive nucleotides of a sequence selected from the group consisting of Sequence ID NO:1, Sequence ID NO:3, Sequence ID NO:5 and Sequence ID NO:7 or a nucleotide sequence complementary to any one of said sequences.
12. An isolated polynucleotide comprising a nucleotide sequence encoding at least one functional domain of a SARA protein.
13. The isolated polynucleotide of any one of the preceding claims wherein the polynucleotide is a polydeoxyribonucleotide.
14. The isolated polynucleotide of any one of claims 1 to 11 wherein the polynucleotide is a polyribonucleotide.
15. An isolated polynucleotide encoding a SARA protein FYVE domain.
16. A recombinant vector comprising the isolated polynucleotide of any one of claims 1 to 15.

17. A host cell comprising the recombinant vector of claim 16.
18. A process for recombinantly producing a SARA protein or a fragment
5 thereof comprising culturing the host cell of claim 17 under conditions whereby the SARA protein or fragment thereof is expressed and isolating the expressed SARA protein or fragment thereof.
19. A substantially pure SARA protein.
10
20. The protein of claim 19 which is a mammalian SARA protein.
21. The protein of claim 19 which is a non-mammalian SARA protein.
- 15 22. The protein of claim 20 which is a human SARA protein.
23. The protein of claim 22 comprising the amino acid sequence of Sequence ID NO:2 or Sequence ID NO:4.
- 20 24. The protein of claim 21 comprising the amino acid sequence of Sequence ID NO:6 or Sequence ID NO:8.
25. A SARA protein that is at least 50 percent identical in amino acid
sequence to the sequence of Sequence ID NO:2 or Sequence ID NO:4.
25
26. The protein of claim 25 wherein the SARA protein has a FYVE domain
having at least 65 percent identity in amino acid sequence to the FYVE domain
of hSARA1 (Sequence ID NO:2) and a C-terminal sequence of 550 consecutive
amino acids which have at least 50 percent identity to the C-terminal 550 amino
30 acid residues of hSARA1.

27. The protein of claim 25 wherein the SARA protein has an FYVE domain having at least 65 percent identity in amino acid sequence to the FYVE domain of hSARA1 (Sequence ID NO:2) and wherein the portion of the SBD corresponding to amino acid residues 721 to 740 of hSARA1 has at least 80 percent identity with that portion of hSARA1.
28. A substantially pure polypeptide comprising an amino acid sequence of at least 4 up to the total number of consecutive amino acids of a sequence selected from the group consisting of Sequence ID NO:2, Sequence ID NO:4, Sequence ID NO:6 and Sequence ID NO:8.
29. A substantially pure polypeptide comprising at least one functional domain of a SARA protein.
30. A substantially pure polypeptide selected from the group consisting of
(a) SASSQSPNPNNAEYCSTIPPLQQAQASGALSSPPPTVMVPV
GVLKHPGAEVAQPREQRRVWFADGILPNGEVADAALKTMNGTSS; and
(b) amino acids 589 to 672 of the XSARA1 sequence of Table 9.
31. A substantially pure polypeptide comprising a SARA protein FYVE domain.
32. The polypeptide of claim 31 comprising a polypeptide selected from the group consisting of
(a) amino acids 587 to 655 of the hSARA1 sequence of Table 9;
(b) amino acids 510 to 578 of the XSARA1 sequence of Table 9;
(c) the consensus amino acid sequence of Table 10; and
(d) a functional fragment of a polypeptide of any of (a) to (c).
33. A substantially pure polypeptide comprising a SARA protein TGF β receptor interacting domain.

34. The polypeptide of claim 33 selected from the group consisting of
- (a) amino acids 751 to 1323 of the hSARA1 sequence of Table 9; and
 - (b) a functional fragment of polypeptide of (a).
- 5
35. A substantially pure antibody which selectively binds to an an antigenic determinant of a SARA protein.
36. A cell line producing the antibody of claim 35.
- 10
37. A method for identifying an allelic variant or homologue of a human SARA gene comprising
- choosing a nucleic acid probe or primer capable of hybridising to a human SARA gene sequence under stringent hybridisation conditions;
 - 15 mixing the probe or primer with a sample of nucleic acids which may contain a nucleic acid corresponding to the homologue variant or homologue; and
 - detecting hybridisation of the probe or primer to the nucleic acid corresponding to the variant or homologue.
- 20
38. A method for modulating signal transduction by a TGF β superfamily member through a SARA protein-dependent pathway, the method comprising modulating the binding of the SARA protein with its binding partner.
- 25
39. The method of claim 38 comprising a method selected from the group consisting of
- (a) modulating the binding of the SARA protein to a Smad binding partner;
 - (b) modulating the binding of the SARA protein FYVE domain to its
 - 30 binding partner; and
 - (c) modulating the binding of the SARA protein to the TGF β receptor.

40. A method for preventing or treating a disorder characterised by an abnormality in a TGF β superfamily member signaling pathway which involves a SARA protein, the method comprising modulating the binding of the SARA protein involved in the pathway with its binding partner.
- 5
41. A method for screening a candidate compound for its potential as a modulator of SARA protein-dependent signaling by a TGF β superfamily member comprising
- 10 (a) determining the ability of the compound to bind to a SARA protein; and
- (b) determining the ability of the compound to alter the phosphorylation state of a SARA protein.
- 15 42. A non-human transgenic animal comprising a polynucleotide encoding a heterologous SARA protein or a portion thereof.
43. The transgenic animal of claim L01 wherein the polynucleotide encodes a human SARA protein or a portion thereof.
- 20 44. A non-human animal having a genome from which the SARA gene has been deleted.




FIGURE 1

1/20






FIGURE 2

2/20



A

Myc-Smad2:	+	-	+	+	+	+
Flag-hSARA:	-	+	-	-	+	+
T β RI:	-	-	WT	A	WT	A






FIGURE 3

3/20






FIGURE 4






FIGURE 5






FIGURE 6






FIGURE 7






FIGURE 8A

8/20






FIGURE 8B






FIGURE 9A

10/20






FIGURE 9B






FIGURE 10






FIGURE 11A




FIGURE 11B






FIGURE 12






FIGURE 13






FIGURE 14






FIGURE 15






FIGURE 16






FIGURE 17






FIGURE 18

